US20130023521A1 - Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications - Google Patents
Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Download PDFInfo
- Publication number
- US20130023521A1 US20130023521A1 US13/521,978 US201113521978A US2013023521A1 US 20130023521 A1 US20130023521 A1 US 20130023521A1 US 201113521978 A US201113521978 A US 201113521978A US 2013023521 A1 US2013023521 A1 US 2013023521A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- aryl
- chloro
- optionally substituted
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 title abstract description 15
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 title abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title abstract description 5
- 229940124639 Selective inhibitor Drugs 0.000 title abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 218
- 125000003118 aryl group Chemical group 0.000 claims description 172
- 150000001875 compounds Chemical class 0.000 claims description 147
- 125000000623 heterocyclic group Chemical group 0.000 claims description 130
- 229910052736 halogen Inorganic materials 0.000 claims description 76
- 150000002367 halogens Chemical class 0.000 claims description 76
- 238000006243 chemical reaction Methods 0.000 claims description 64
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 59
- 125000005842 heteroatom Chemical group 0.000 claims description 47
- -1 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(benzyl-ethyl-amino)-propyl]-amide 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-dipropylamino-propyl)-amide Chemical compound 0.000 claims description 31
- 229910052701 rubidium Inorganic materials 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 125000002950 monocyclic group Chemical group 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- CMSADOAGVKNBGR-UHFFFAOYSA-N 9-chloro-n-[2-(diethylamino)ethyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NCCN(CC)CC)=CC=C3C(Cl)=C21 CMSADOAGVKNBGR-UHFFFAOYSA-N 0.000 claims description 12
- 229910003827 NRaRb Inorganic materials 0.000 claims description 10
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- SODROUATTJNBGY-UHFFFAOYSA-N 9-chloro-n-(2-piperidin-1-ylethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCN1CCCCC1 SODROUATTJNBGY-UHFFFAOYSA-N 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- WBIKDLIOIPPDKH-UHFFFAOYSA-N 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid Chemical compound C1CCCC2=NC3=CC(C(=O)O)=CC=C3C(Cl)=C21 WBIKDLIOIPPDKH-UHFFFAOYSA-N 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 229960000103 thrombolytic agent Drugs 0.000 claims description 4
- 102000052151 Ubiquitin-Specific Peptidase 7 Human genes 0.000 claims description 3
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 206010001258 Adenoviral infections Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 206010039105 Rhinoviral infections Diseases 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- WUOQKLAFSWIFFA-UHFFFAOYSA-N (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methanone;(9-chloro-5,6,7,8-tetrahydroacridin-3-yl)-piperidin-1-ylmethanone Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)N1CCCCC1.C1CN(C)CCC1N1CCN(C(=O)C=2C=C3N=C4CCCCC4=C(Cl)C3=CC=2)CC1 WUOQKLAFSWIFFA-UHFFFAOYSA-N 0.000 claims 2
- LKJVSXWWJSXFDN-UHFFFAOYSA-N 9-chloro-N-[[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide 9-chloro-N-[[4-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCC1CCN(CC1)CC1=CC=C(C=C1)OC.ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCC1=CC=C(C=C1)CN1CCCC1 LKJVSXWWJSXFDN-UHFFFAOYSA-N 0.000 claims 2
- JXRCWGDAPTUVBC-UHFFFAOYSA-N 9-chloro-n-[3-hydroxy-3-phenyl-2-(pyrrolidin-1-ylmethyl)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide;9-chloro-n-(piperidin-4-ylmethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC1CCNCC1.C=1C=CC=CC=1C(O)C(CNC(=O)C=1C=C2N=C3CCCCC3=C(Cl)C2=CC=1)CN1CCCC1 JXRCWGDAPTUVBC-UHFFFAOYSA-N 0.000 claims 2
- OYXWBCCJLXORKK-UHFFFAOYSA-N ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NC1=CC(=CC=C1)CN1CCCC1.ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCC1=CC(=CC=C1)CN1CCCC1 Chemical compound ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NC1=CC(=CC=C1)CN1CCCC1.ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCC1=CC(=CC=C1)CN1CCCC1 OYXWBCCJLXORKK-UHFFFAOYSA-N 0.000 claims 2
- NIPOISJLKHUNMQ-UHFFFAOYSA-N ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCCC1N(CCC1)C.ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCCCN1C(CCCC1)C Chemical compound ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCCC1N(CCC1)C.ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NCCCN1C(CCCC1)C NIPOISJLKHUNMQ-UHFFFAOYSA-N 0.000 claims 2
- SVEKQFAVABLJAV-ZWZQDMJTSA-N ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NC[C@H]1N(CCC1)CC.ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NC[C@@H]1N(CCC1)CC Chemical compound ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NC[C@H]1N(CCC1)CC.ClC=1C=2CCCCC2N=C2C=C(C=CC12)C(=O)NC[C@@H]1N(CCC1)CC SVEKQFAVABLJAV-ZWZQDMJTSA-N 0.000 claims 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 2
- IXRTVJAJWYCWFB-UHFFFAOYSA-N n-[(1-benzylpiperidin-4-yl)methyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide;9-chloro-n-[[1-(3-phenylpropyl)piperidin-4-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC(CC1)CCN1CC1=CC=CC=C1.C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC(CC1)CCN1CCCC1=CC=CC=C1 IXRTVJAJWYCWFB-UHFFFAOYSA-N 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- BQQPTPWBIJXTOA-UHFFFAOYSA-N C(C)N1C(CCC1)CNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl.CC=1C=C(CN2CCC(CC2)CNC(=O)C=2C=CC3=C(C=4CCCCC4N=C3C2)Cl)C=CC1 Chemical compound C(C)N1C(CCC1)CNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl.CC=1C=C(CN2CCC(CC2)CNC(=O)C=2C=CC3=C(C=4CCCCC4N=C3C2)Cl)C=CC1 BQQPTPWBIJXTOA-UHFFFAOYSA-N 0.000 claims 1
- CNJHSBKLZDKRLG-UHFFFAOYSA-N C(CCC)N(CCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl)CC.C(CC)N(CCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl)CCC Chemical compound C(CCC)N(CCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl)CC.C(CC)N(CCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl)CCC CNJHSBKLZDKRLG-UHFFFAOYSA-N 0.000 claims 1
- HZTHZTRJEAGLMG-UHFFFAOYSA-N CN1CCN(CCCN)CC1.O=C(C1=CC2=NC(CCCC3)=C3C(Cl)=C2C=C1)N(CC1)CCC1N1CCCCC1 Chemical compound CN1CCN(CCCN)CC1.O=C(C1=CC2=NC(CCCC3)=C3C(Cl)=C2C=C1)N(CC1)CCC1N1CCCCC1 HZTHZTRJEAGLMG-UHFFFAOYSA-N 0.000 claims 1
- IZTGZAWOBGUBPT-UHFFFAOYSA-N Clc1c2CCCCc2nc2cc(ccc12)C(=O)N1CCCCCC1.Clc1c2CCCCc2nc2cc(ccc12)C(=O)NCCCN1CCCC1 Chemical compound Clc1c2CCCCc2nc2cc(ccc12)C(=O)N1CCCCCC1.Clc1c2CCCCc2nc2cc(ccc12)C(=O)NCCCN1CCCC1 IZTGZAWOBGUBPT-UHFFFAOYSA-N 0.000 claims 1
- HAXXTBOUZZKEGM-UHFFFAOYSA-N N1(CCCC1)CCCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl.C(C)N(CCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl)CC Chemical compound N1(CCCC1)CCCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl.C(C)N(CCNC(=O)C=1C=CC2=C(C=3CCCCC3N=C2C1)Cl)CC HAXXTBOUZZKEGM-UHFFFAOYSA-N 0.000 claims 1
- 101150020913 USP7 gene Proteins 0.000 claims 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 claims 1
- KTCHLUXDJKTESF-UHFFFAOYSA-N n-[2-(azepan-1-yl)ethyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide;9-chloro-n-(2-piperidin-1-ylethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCN1CCCCC1.C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCN1CCCCCC1 KTCHLUXDJKTESF-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 35
- 238000002360 preparation method Methods 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 66
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 102000004190 Enzymes Human genes 0.000 description 28
- 108090000790 Enzymes Proteins 0.000 description 28
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 27
- 238000003556 assay Methods 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 239000000758 substrate Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 101000841466 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 8 Proteins 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 102100029088 Ubiquitin carboxyl-terminal hydrolase 8 Human genes 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 229940098773 bovine serum albumin Drugs 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 10
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 10
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
- 102000044159 Ubiquitin Human genes 0.000 description 10
- 238000009833 condensation Methods 0.000 description 10
- 230000005494 condensation Effects 0.000 description 10
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 10
- 150000002576 ketones Chemical class 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- OTMSDBZUPAUEDD-UHFFFAOYSA-N CC Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 9
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N CCC Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 108090000848 Ubiquitin Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- NDVNRMFVHPDGAY-UHFFFAOYSA-N 9-chloro-n-(3-pyrrolidin-1-ylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCCN1CCCC1 NDVNRMFVHPDGAY-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 102000005927 Cysteine Proteases Human genes 0.000 description 7
- 108010005843 Cysteine Proteases Proteins 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 239000013504 Triton X-100 Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 230000026030 halogenation Effects 0.000 description 7
- 238000005658 halogenation reaction Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- INENHQAHSJRSRN-UHFFFAOYSA-N 9-chloro-n-(piperidin-4-ylmethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC1CCNCC1 INENHQAHSJRSRN-UHFFFAOYSA-N 0.000 description 6
- WNWBKQHCJXCPDE-UHFFFAOYSA-N 9-chloro-n-[3-(diethylamino)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NCCCN(CC)CC)=CC=C3C(Cl)=C21 WNWBKQHCJXCPDE-UHFFFAOYSA-N 0.000 description 6
- ZIWXIXIPOUYQJF-UHFFFAOYSA-N 9-chloro-n-[3-hydroxy-3-phenyl-2-(pyrrolidin-1-ylmethyl)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=CC=CC=1C(O)C(CNC(=O)C=1C=C2N=C3CCCCC3=C(Cl)C2=CC=1)CN1CCCC1 ZIWXIXIPOUYQJF-UHFFFAOYSA-N 0.000 description 6
- QMZKXXNKCWAXNZ-UHFFFAOYSA-N 9-chloro-n-[[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(CNC(=O)C=2C=C3N=C4CCCCC4=C(Cl)C3=CC=2)CC1 QMZKXXNKCWAXNZ-UHFFFAOYSA-N 0.000 description 6
- RWNLZPUCCQFYIJ-UHFFFAOYSA-N 9-chloro-n-[[4-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC(C=C1)=CC=C1CN1CCCC1 RWNLZPUCCQFYIJ-UHFFFAOYSA-N 0.000 description 6
- GHRCOWOBRBCVKL-UHFFFAOYSA-N 9-oxo-6,7,8,10-tetrahydro-5h-acridine-3-carboxylic acid Chemical compound C1CCCC2=C1NC1=CC(C(=O)O)=CC=C1C2=O GHRCOWOBRBCVKL-UHFFFAOYSA-N 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- PEISGDLUWUOZQM-UHFFFAOYSA-N azepan-1-yl-(9-chloro-5,6,7,8-tetrahydroacridin-3-yl)methanone Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)N1CCCCCC1 PEISGDLUWUOZQM-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 6
- 238000007306 functionalization reaction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000030279 gene silencing Effects 0.000 description 6
- HZSMLOMFQAOLDQ-UHFFFAOYSA-N n-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCCN(C)CC1=CC=CC=C1 HZSMLOMFQAOLDQ-UHFFFAOYSA-N 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- BKZAMTKRSXCQBB-UHFFFAOYSA-N (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methanone Chemical compound C1CN(C)CCC1N1CCN(C(=O)C=2C=C3N=C4CCCCC4=C(Cl)C3=CC=2)CC1 BKZAMTKRSXCQBB-UHFFFAOYSA-N 0.000 description 5
- MMKPENQLGOMUAQ-UHFFFAOYSA-N (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)-[4-[(1-methylpiperidin-4-yl)methyl]piperazin-1-yl]methanone Chemical compound C1CN(C)CCC1CN1CCN(C(=O)C=2C=C3N=C4CCCCC4=C(Cl)C3=CC=2)CC1 MMKPENQLGOMUAQ-UHFFFAOYSA-N 0.000 description 5
- CEQDUZLECVOVNF-UHFFFAOYSA-N (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)-piperidin-1-ylmethanone Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)N1CCCCC1 CEQDUZLECVOVNF-UHFFFAOYSA-N 0.000 description 5
- AHJCKTNRWJGOKV-UHFFFAOYSA-N 9-chloro-N-[[1-(1-phenylethyl)piperidin-4-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CC(CNC(=O)C=2C=C3N=C4CCCCC4=C(Cl)C3=CC=2)CCN1C(C)C1=CC=CC=C1 AHJCKTNRWJGOKV-UHFFFAOYSA-N 0.000 description 5
- DGWMMZMTYNKYLU-UHFFFAOYSA-N 9-chloro-n-[3-(4-methylpiperazin-1-yl)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CN(C)CCN1CCCNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 DGWMMZMTYNKYLU-UHFFFAOYSA-N 0.000 description 5
- BUWIVHUIKBQDRY-UHFFFAOYSA-N 9-chloro-n-[3-(4-propylpiperazin-1-yl)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CN(CCC)CCN1CCCNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 BUWIVHUIKBQDRY-UHFFFAOYSA-N 0.000 description 5
- ZCKLCTAIDNDQQV-UHFFFAOYSA-N 9-chloro-n-[3-(dimethylamino)-2,2-dimethylpropyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NCC(C)(C)CN(C)C)=CC=C3C(Cl)=C21 ZCKLCTAIDNDQQV-UHFFFAOYSA-N 0.000 description 5
- OWMJRFHKFOYTNF-UHFFFAOYSA-N 9-chloro-n-[3-(dipropylamino)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NCCCN(CCC)CCC)=CC=C3C(Cl)=C21 OWMJRFHKFOYTNF-UHFFFAOYSA-N 0.000 description 5
- PQQGECPJYZYELE-UHFFFAOYSA-N 9-chloro-n-[3-(pyrrolidin-1-ylmethyl)phenyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NC(C=1)=CC=CC=1CN1CCCC1 PQQGECPJYZYELE-UHFFFAOYSA-N 0.000 description 5
- ZGHGUMWMLANHGH-UHFFFAOYSA-N 9-chloro-n-[5-(diethylamino)pentan-2-yl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NC(C)CCCN(CC)CC)=CC=C3C(Cl)=C21 ZGHGUMWMLANHGH-UHFFFAOYSA-N 0.000 description 5
- KOLPEHROICNEKA-UHFFFAOYSA-N 9-chloro-n-[[1-(3-phenylpropyl)piperidin-4-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC(CC1)CCN1CCCC1=CC=CC=C1 KOLPEHROICNEKA-UHFFFAOYSA-N 0.000 description 5
- NYYLFPZMXQKHJO-UHFFFAOYSA-N 9-chloro-n-[[1-[(3-methylphenyl)methyl]piperidin-4-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound CC1=CC=CC(CN2CCC(CNC(=O)C=3C=C4N=C5CCCCC5=C(Cl)C4=CC=3)CC2)=C1 NYYLFPZMXQKHJO-UHFFFAOYSA-N 0.000 description 5
- QJNNHGUIVUBNRL-UHFFFAOYSA-N 9-chloro-n-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC(C=1)=CC=CC=1CN1CCCC1 QJNNHGUIVUBNRL-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 229960003722 doxycycline Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- MLSWKGZKKFERDA-UHFFFAOYSA-N n-[(1-benzylpiperidin-4-yl)methyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCC(CC1)CCN1CC1=CC=CC=C1 MLSWKGZKKFERDA-UHFFFAOYSA-N 0.000 description 5
- PIALYNPAIGETID-UHFFFAOYSA-N n-[2-(azepan-1-yl)ethyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCN1CCCCCC1 PIALYNPAIGETID-UHFFFAOYSA-N 0.000 description 5
- YOPQCPNKEFBBFI-UHFFFAOYSA-N n-[3-[benzyl(ethyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCCN(CC)CC1=CC=CC=C1 YOPQCPNKEFBBFI-UHFFFAOYSA-N 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010042785 ubiquitin C-terminal 7-amido-4-methylcoumarin Proteins 0.000 description 5
- LVKVMTLXBQFRMT-UHFFFAOYSA-N (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)-(4-piperidin-1-ylpiperidin-1-yl)methanone Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)N(CC1)CCC1N1CCCCC1 LVKVMTLXBQFRMT-UHFFFAOYSA-N 0.000 description 4
- 0 *.*C(C)=O.B.C.C/C1=C2\CC(C)C\C2=N\C2=CC=CC=C21.CC Chemical compound *.*C(C)=O.B.C.C/C1=C2\CC(C)C\C2=N\C2=CC=CC=C21.CC 0.000 description 4
- IDLAOWFFKWRNHB-UHFFFAOYSA-N 4,5,6,7-tetrachloroindene-1,3-dione Chemical compound ClC1=C(Cl)C(Cl)=C2C(=O)CC(=O)C2=C1Cl IDLAOWFFKWRNHB-UHFFFAOYSA-N 0.000 description 4
- ZUJAQNXITNYJQA-OAHLLOKOSA-N 9-chloro-n-[[(2r)-1-ethylpyrrolidin-2-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound CCN1CCC[C@@H]1CNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 ZUJAQNXITNYJQA-OAHLLOKOSA-N 0.000 description 4
- ZUJAQNXITNYJQA-HNNXBMFYSA-N 9-chloro-n-[[(2s)-1-ethylpyrrolidin-2-yl]methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 ZUJAQNXITNYJQA-HNNXBMFYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 4
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000643890 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 5 Proteins 0.000 description 4
- 229910019213 POCl3 Inorganic materials 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 102000008880 Peptidase C12, ubiquitin carboxyl-terminal hydrolases Human genes 0.000 description 4
- 108050000823 Peptidase C12, ubiquitin carboxyl-terminal hydrolases Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 102100021017 Ubiquitin carboxyl-terminal hydrolase 5 Human genes 0.000 description 4
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 4
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 4
- 102100025040 Ubiquitin carboxyl-terminal hydrolase isozyme L3 Human genes 0.000 description 4
- 101710186831 Ubiquitin carboxyl-terminal hydrolase isozyme L3 Proteins 0.000 description 4
- OPQRFPHLZZPCCH-PGMHBOJBSA-N [(z)-[5-chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate Chemical compound C12=CC=C(Cl)C=C2C(=N/OC(=O)C)/C(=O)N1CC1=CC(Cl)=CC=C1Cl OPQRFPHLZZPCCH-PGMHBOJBSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 125000005936 piperidyl group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- MEVZSZBBKHNDMP-UHFFFAOYSA-N *.B.C.CC.CC.CC(=O)O.O=C1C2=CC=CC=C2/N=C2/CCCC12 Chemical compound *.B.C.CC.CC.CC(=O)O.O=C1C2=CC=CC=C2/N=C2/CCCC12 MEVZSZBBKHNDMP-UHFFFAOYSA-N 0.000 description 3
- MEFLBDDXWJTFIR-UHFFFAOYSA-N 1-carbazol-9-yl-3-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]propan-2-ol Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1CC(O)CN(CC1)CCN1CC1=CC=C(Cl)C=C1 MEFLBDDXWJTFIR-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- MUBMTHNOZGWXOP-UHFFFAOYSA-N 9-chloro-n-[2-(1-methylpyrrolidin-2-yl)ethyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound CN1CCCC1CCNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 MUBMTHNOZGWXOP-UHFFFAOYSA-N 0.000 description 3
- RTVIEWCSIBSIKL-UHFFFAOYSA-N 9-chloro-n-[3-(2-methylpiperidin-1-yl)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound CC1CCCCN1CCCNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 RTVIEWCSIBSIKL-UHFFFAOYSA-N 0.000 description 3
- RHRTWHVKBGMDRF-UHFFFAOYSA-N 9-chloro-n-[3-(3,4-dihydro-1h-isoquinolin-2-yl)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CC2=CC=CC=C2CN1CCCNC(=O)C1=CC=C2C(Cl)=C(CCCC3)C3=NC2=C1 RHRTWHVKBGMDRF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 238000012056 up-stream process Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- KCEGPBQRLOBDEE-UHFFFAOYSA-N *.*.*.*.B.B.B.B.C.C.C.C.O=C(O)C1=C2C(=O)C3CCCC3=NC2=CC=C1.O=C(O)C1=C2N=C3CCCC3C(=O)C2=CC=C1.O=C(O)C1=CC=C2C(=O)C3CCCC3=NC2=C1.O=C(O)C1=CC=C2N=C3CCCC3C(=O)C2=C1 Chemical compound *.*.*.*.B.B.B.B.C.C.C.C.O=C(O)C1=C2C(=O)C3CCCC3=NC2=CC=C1.O=C(O)C1=C2N=C3CCCC3C(=O)C2=CC=C1.O=C(O)C1=CC=C2C(=O)C3CCCC3=NC2=C1.O=C(O)C1=CC=C2N=C3CCCC3C(=O)C2=C1 KCEGPBQRLOBDEE-UHFFFAOYSA-N 0.000 description 2
- TVOFDSXMASYGEM-UHFFFAOYSA-M *.B.C.CC.CC.CC1=C2CCCCC2=NC2=CC(C(=O)N(C)[Y])=CC=C21 Chemical compound *.B.C.CC.CC.CC1=C2CCCCC2=NC2=CC(C(=O)N(C)[Y])=CC=C21 TVOFDSXMASYGEM-UHFFFAOYSA-M 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 2
- GPNNOCMCNFXRAO-UHFFFAOYSA-N 2-aminoterephthalic acid Chemical class NC1=CC(C(O)=O)=CC=C1C(O)=O GPNNOCMCNFXRAO-UHFFFAOYSA-N 0.000 description 2
- HQNQEJUMXCNZFX-UHFFFAOYSA-N 9-chloro-5,6,7,8-tetrahydroacridine-2-carboxylic acid Chemical compound C1CCCC2=C(Cl)C3=CC(C(=O)O)=CC=C3N=C21 HQNQEJUMXCNZFX-UHFFFAOYSA-N 0.000 description 2
- PRKOUXUUULCYID-UHFFFAOYSA-N 9-chloro-5,6,7,8-tetrahydroacridine-4-carboxylic acid Chemical compound C1CCCC2=C1C(Cl)=C1C=CC=C(C(=O)O)C1=N2 PRKOUXUUULCYID-UHFFFAOYSA-N 0.000 description 2
- ZUJAQNXITNYJQA-UHFFFAOYSA-N 9-chloro-n-[(1-ethylpyrrolidin-2-yl)methyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 ZUJAQNXITNYJQA-UHFFFAOYSA-N 0.000 description 2
- FILULDVZTWDGNH-UHFFFAOYSA-N 9-chloro-n-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NCCN(C)C)=CC=C3C(Cl)=C21 FILULDVZTWDGNH-UHFFFAOYSA-N 0.000 description 2
- VNJJTVWEIGMVDB-UHFFFAOYSA-N 9-chloro-n-[2-(dipropylamino)ethyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NCCN(CCC)CCC)=CC=C3C(Cl)=C21 VNJJTVWEIGMVDB-UHFFFAOYSA-N 0.000 description 2
- CVNINRBYCRBAIF-UHFFFAOYSA-N 9-chloro-n-[3-(2,6-dimethylpiperidin-1-yl)propyl]-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound CC1CCCC(C)N1CCCNC(=O)C1=CC=C(C(Cl)=C2C(CCCC2)=N2)C2=C1 CVNINRBYCRBAIF-UHFFFAOYSA-N 0.000 description 2
- SLTUXKJWYHGCJS-UHFFFAOYSA-N 9-oxo-6,7,8,10-tetrahydro-5h-acridine-4-carboxylic acid Chemical compound C1CCCC(C2=O)=C1NC1=C2C=CC=C1C(=O)O SLTUXKJWYHGCJS-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- UPZBLOTWNHDLQR-UHFFFAOYSA-M B.C.CC.CC.CC(=O)N(C)[Y].CC1=C2CCCC2=NC2=CC=CC=C21 Chemical compound B.C.CC.CC.CC(=O)N(C)[Y].CC1=C2CCCC2=NC2=CC=CC=C21 UPZBLOTWNHDLQR-UHFFFAOYSA-M 0.000 description 2
- MEKDPHXPVMKCON-UHFFFAOYSA-N C.CC Chemical compound C.CC MEKDPHXPVMKCON-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 101150057615 Syn gene Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 2
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N [H]N(C)C Chemical compound [H]N(C)C ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- WNIWGIPDBPZRPF-UHFFFAOYSA-N n-[2-[butyl(ethyl)amino]ethyl]-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C1CCCC2=NC3=CC(C(=O)NCCN(CC)CCCC)=CC=C3C(Cl)=C21 WNIWGIPDBPZRPF-UHFFFAOYSA-N 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- ALZSTTDFHZHSCA-RNVDEAKXSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 ALZSTTDFHZHSCA-RNVDEAKXSA-N 0.000 description 1
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- REBDVDXNQQXNMC-UHFFFAOYSA-N *.B.C.CC.CC.CC(=O)O.O=C1C2=CC=CC=C2/N=C2/CCCCC12 Chemical compound *.B.C.CC.CC.CC(=O)O.O=C1C2=CC=CC=C2/N=C2/CCCCC12 REBDVDXNQQXNMC-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- QLZBCIAHOPMRLV-UHFFFAOYSA-N 11-chloro-7,8,9,10-tetrahydro-6h-cyclohepta[b]quinoline-3-carboxylic acid Chemical compound C1CCCCC2=NC3=CC(C(=O)O)=CC=C3C(Cl)=C21 QLZBCIAHOPMRLV-UHFFFAOYSA-N 0.000 description 1
- BBUPBICWUURTNP-UHFFFAOYSA-N 2,4-dimethyl-1-nitrobenzene Chemical group CC1=CC=C([N+]([O-])=O)C(C)=C1 BBUPBICWUURTNP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- BDBLLWHZWCBDAR-UHFFFAOYSA-N 4-aminobenzene-1,3-dicarboxylic acid Chemical compound NC1=CC=C(C(O)=O)C=C1C(O)=O BDBLLWHZWCBDAR-UHFFFAOYSA-N 0.000 description 1
- OCJFXVHDIVAONP-UHFFFAOYSA-N 4-nitroisophthalic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 OCJFXVHDIVAONP-UHFFFAOYSA-N 0.000 description 1
- XKLARLROPXOXRP-UHFFFAOYSA-N 5,6,7,8-tetrahydroacridine-3-carboxylic acid Chemical compound C1CCCC2=NC3=CC(C(=O)O)=CC=C3C=C21 XKLARLROPXOXRP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- BLQFGMTYRJWPAH-UHFFFAOYSA-N 9-bromo-5,6,7,8-tetrahydroacridine-3-carboxylic acid Chemical compound C1CCCC2=NC3=CC(C(=O)O)=CC=C3C(Br)=C21 BLQFGMTYRJWPAH-UHFFFAOYSA-N 0.000 description 1
- IDLSFCKOZHWZBS-UHFFFAOYSA-N 9-chloro-n-(3-morpholin-4-ylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide Chemical compound C=1C=C2C(Cl)=C3CCCCC3=NC2=CC=1C(=O)NCCCN1CCOCC1 IDLSFCKOZHWZBS-UHFFFAOYSA-N 0.000 description 1
- MYZVKJPWLLKBLT-UHFFFAOYSA-N 9-methyl-5,6,7,8-tetrahydroacridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(C)=C(CCCC3)C3=NC2=C1 MYZVKJPWLLKBLT-UHFFFAOYSA-N 0.000 description 1
- 108010021160 Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- JOBOOHUKSRRGRO-UHFFFAOYSA-M B.C.CC.CC.CC1=C2CCCC2=NC2=CC(C(=O)N(C)[Y])=CC=C21 Chemical compound B.C.CC.CC.CC1=C2CCCC2=NC2=CC(C(=O)N(C)[Y])=CC=C21 JOBOOHUKSRRGRO-UHFFFAOYSA-M 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NHDZESQHWMKRPE-UHFFFAOYSA-N C.C.CCC Chemical compound C.C.CCC NHDZESQHWMKRPE-UHFFFAOYSA-N 0.000 description 1
- YBRVKRUPGIAILO-UHFFFAOYSA-N C1CCCC1.C1CCCCC1.C1CCCCCC1.C1CCNCC1.C1CCNCC1.C1CCNCC1.C1CCOCC1.C1CCOCC1 Chemical compound C1CCCC1.C1CCCCC1.C1CCCCCC1.C1CCNCC1.C1CCNCC1.C1CCNCC1.C1CCOCC1.C1CCOCC1 YBRVKRUPGIAILO-UHFFFAOYSA-N 0.000 description 1
- MWEKXPZCOAUOBI-UHFFFAOYSA-N CC1=CC=C([N+](=O)[O-])C(C)=C1.O=C(O)C1=CC=C2N=C3CCCCC3=C(Cl)C2=C1.O=C=O.O=C=O.O=C=O.[H]C1=CC=C(N)C(C(=O)O)=C1.[H]C1=CC=C([N+](=O)[O-])C(C(=O)O)=C1.[H]C1=CC=C2NC3=C(CCCC3)C(=O)C2=C1 Chemical compound CC1=CC=C([N+](=O)[O-])C(C)=C1.O=C(O)C1=CC=C2N=C3CCCCC3=C(Cl)C2=C1.O=C=O.O=C=O.O=C=O.[H]C1=CC=C(N)C(C(=O)O)=C1.[H]C1=CC=C([N+](=O)[O-])C(C(=O)O)=C1.[H]C1=CC=C2NC3=C(CCCC3)C(=O)C2=C1 MWEKXPZCOAUOBI-UHFFFAOYSA-N 0.000 description 1
- CIBZIEKRMGOLMD-UHFFFAOYSA-N CCOC(=O)C1=CC=C2C(=C1)N=C1CCCCC1=C2Br.CCOC(=O)C1=CC=C2C(=C1)N=C1CCCCC1=C2C.O=C(O)C1=CC=C2C(=C1)N=C1CCCCC1=C2Br.O=C(O)C1=CC=C2C(=C1)N=C1CCCCC1=C2Cl.O=C(O)C1=CC=C2C(=O)C3=C(CCCC3)NC2=C1.O=C(O)C1=CC=C2C=C3CCCCC3=NC2=C1 Chemical compound CCOC(=O)C1=CC=C2C(=C1)N=C1CCCCC1=C2Br.CCOC(=O)C1=CC=C2C(=C1)N=C1CCCCC1=C2C.O=C(O)C1=CC=C2C(=C1)N=C1CCCCC1=C2Br.O=C(O)C1=CC=C2C(=C1)N=C1CCCCC1=C2Cl.O=C(O)C1=CC=C2C(=O)C3=C(CCCC3)NC2=C1.O=C(O)C1=CC=C2C=C3CCCCC3=NC2=C1 CIBZIEKRMGOLMD-UHFFFAOYSA-N 0.000 description 1
- VVTMOGOHVWRHKN-UHFFFAOYSA-N CN(C)C1=CC=C(CN2CCC(CNC(=O)C3=CC=C4C(=C3)N=C3CCCCC3=C4Cl)CC2)C=C1 Chemical compound CN(C)C1=CC=C(CN2CCC(CNC(=O)C3=CC=C4C(=C3)N=C3CCCCC3=C4Cl)CC2)C=C1 VVTMOGOHVWRHKN-UHFFFAOYSA-N 0.000 description 1
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 description 1
- 101100208731 Caenorhabditis elegans math-33 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 102100040484 Claspin Human genes 0.000 description 1
- 101710117926 Claspin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 102100035416 Forkhead box protein O4 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000877683 Homo sapiens Forkhead box protein O4 Proteins 0.000 description 1
- 101000658628 Homo sapiens Testis-specific Y-encoded-like protein 5 Proteins 0.000 description 1
- 101000643908 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 7 Proteins 0.000 description 1
- 101000840051 Homo sapiens Ubiquitin-60S ribosomal protein L40 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 101150090364 ICP0 gene Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 238000005645 Mc Coy reaction Methods 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 101100519086 Mus musculus Pcgf2 gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- BWUJIGLQEWXYCY-UHFFFAOYSA-N NC1=C(C(=O)O)C=CC=C1C(=O)O.O=C(O)C1=C2/N=C3/CCCC/C3=C(\Cl)C2=CC=C1.O=C(O)C1=C2NC3=C(CCCC3)C(=O)C2=CC=C1 Chemical compound NC1=C(C(=O)O)C=CC=C1C(=O)O.O=C(O)C1=C2/N=C3/CCCC/C3=C(\Cl)C2=CC=C1.O=C(O)C1=C2NC3=C(CCCC3)C(=O)C2=CC=C1 BWUJIGLQEWXYCY-UHFFFAOYSA-N 0.000 description 1
- VKIUQVYHDPZFHX-UHFFFAOYSA-N NC1=CC(C(=O)O)=CC=C1C(=O)O.O=C(O)C1=CC=C2C(=C1)/N=C1/CCCC/C1=C/2Cl.O=C(O)C1=CC=C2C(=O)C3=C(CCCC3)NC2=C1 Chemical compound NC1=CC(C(=O)O)=CC=C1C(=O)O.O=C(O)C1=CC=C2C(=C1)/N=C1/CCCC/C1=C/2Cl.O=C(O)C1=CC=C2C(=O)C3=C(CCCC3)NC2=C1 VKIUQVYHDPZFHX-UHFFFAOYSA-N 0.000 description 1
- VVZKAKIDZBWAKN-UHFFFAOYSA-N NC1=CC(C(=O)O)=CC=C1C(=O)O.O=C(O)C1=CC=C2C(=C1)NC1=C(CCCCC1)C2Cl.O=C(O)C1=CC=C2C(=O)C3=C(CCCCC3)NC2=C1 Chemical compound NC1=CC(C(=O)O)=CC=C1C(=O)O.O=C(O)C1=CC=C2C(=C1)NC1=C(CCCCC1)C2Cl.O=C(O)C1=CC=C2C(=O)C3=C(CCCCC3)NC2=C1 VVZKAKIDZBWAKN-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108090000794 Streptopain Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 102100034914 Testis-specific Y-encoded-like protein 5 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108091034406 USP family Proteins 0.000 description 1
- 102100028462 Ubiquitin-60S ribosomal protein L40 Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 239000011903 deuterated solvents Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 229950008932 epolamine Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- VXWOUNRSUJHKGE-UHFFFAOYSA-N ethyl 9-bromo-5,6,7,8-tetrahydroacridine-3-carboxylate Chemical compound C1CCCC2=NC3=CC(C(=O)OCC)=CC=C3C(Br)=C21 VXWOUNRSUJHKGE-UHFFFAOYSA-N 0.000 description 1
- GGSCKGUVMMGDJB-UHFFFAOYSA-N ethyl 9-methyl-5,6,7,8-tetrahydroacridine-3-carboxylate Chemical compound C1CCCC2=NC3=CC(C(=O)OCC)=CC=C3C(C)=C21 GGSCKGUVMMGDJB-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 239000012585 homogenous medium Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000056365 human USP7 Human genes 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- TZXOBVNXNDFQCL-UHFFFAOYSA-N methyl 9-bromo-5,6,7,8-tetrahydroacridine-3-carboxylate Chemical compound C1CCCC2=NC3=CC(C(=O)OC)=CC=C3C(Br)=C21 TZXOBVNXNDFQCL-UHFFFAOYSA-N 0.000 description 1
- HBYHLPGXXHOQJE-UHFFFAOYSA-N methyl 9-methyl-5,6,7,8-tetrahydroacridine-3-carboxylate Chemical compound C1CCCC2=NC3=CC(C(=O)OC)=CC=C3C(C)=C21 HBYHLPGXXHOQJE-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
- Ubiquitin specific proteases are cysteines proteases which belong to the deubiquitinylation enzymes (DUBs) family.
- Deregulation of the ubiquitin-proteasome system has been implicated in the pathogenesis of many human diseases, including cancer (Hoeller et al. Nat Rev Cancer 2006, 6(10), 776-788), neurodegenerative disorders (Rubinsztein, Nature 2006, 443(7113), 780-786) and viral diseases (Gao & Luo Can J Physiol Pharmacol 2006, 84(1), 5-14).
- the market success of the proteasome inhibitor Velcade® (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma has established this system as a valid target for cancer treatment (Adams, Nat Rev Cancer 2004, 4(5), 349-360).
- a promising alternative to targeting the proteasome itself would be to interfere with the upstream ubiquitin conjugation/deconjugation machinery, to generate more specific, less toxic anticancer agents.
- Mono- and polyubiquitination can be reversed by deubiquitinating enzymes, which specifically cleave the isopeptide bond at the C-terminus of ubiquitin.
- Ubiquitin specific proteases and ubiquitin C-terminal hydrolases (UCH) enzymes are the best characterized members of the DUB family (Komander et al. Nat. Rev. Mol. Cell Biol. 2009, 10(8), 550-63; Nijman et al. Cell 2005, 123(5), 773-786).
- UCHs are thought to cleave small protein substrates preferentially and to be involved principally in the processing and recycling of ubiquitin, but their specific functions remain poorly understood.
- USPs constitute the largest subfamily of DUBs, with more than 60 members.
- USPs are emerging as potential targets for pharmacological interference with the ubiquitin regulation machinery, based on their protease activity and involvement in several human diseases.
- USP7 Ubiquitin Specific Protease 7/HAUSP (Herpes Associated Ubiquitin Specific Protease) is a 135 kDa protein of the USP family. USP7 has been shown to interact with viral proteins, such as ICP0 (Vmw 11.0), a herpes simplex virus immediate-early gene stimulating initiation of the viral lytic cycle (Everett et al., J Virol 73, 1999, 417-426), and EBNA1 (Epstein-Barr Nuclear Antigen-1) (Holowaty et al., J Biol Chem 2003, 278, 29987-29994 and 47753-47761).
- ICP0 Vmw 11.0
- EBNA1 Epstein-Barr Nuclear Antigen-1
- USP7 also alters the level of the p16 INK4a tumor suppressor through Bmi1/Mel18 stabilization (Maertens et al., Embo J. 2010 29, 2553-2565). Additional proteins involved in genomic integrity/regulation such as the DNMT1 DNA methylase and the Claspin adaptor are also stabilized by USP7 (Du et al., Science Signaling 2010, 3(146):ra80; Faustrup et al., J. Cell Biol. 2009, 184(1):13-9).
- USP7 and DNMT1 a protein involved in maintaining epigenetic methylation required to silence genes involved in development and cancer, correlates in human colon cancer (Du et al, Science Signaling, 2010, 3(146):ra80). USP7 has also been shown in human cells to deubiquitinate the well-known tumor suppressor gene PTEN, which provokes its nuclear export and hence its inactivation (Song et al., Nature 2008, 455(7214), 813-7). More importantly, USP7 overexpression was reported for the first time in prostate cancer and this overexpression was directly associated with tumour aggressiveness (Song et al., Nature 2008, 455(7214), 813-7).
- USP7 has also been shown in human cells to deubiquitinate FOXO4, which provokes its nuclear export and hence its inactivation; consequently the oncogenic PI3K/PKB signaling pathway was activated (van der Horst et al., Nat Cell Biol. 2006, 8, 1064-1073) Finally, USP7 plays an important role in p53-mediated cellular responses to various types of stress, such as DNA damage and oxidative stress (Marchenko et al., Embo J. 2007 26, 923-934, Meulmeester at al. Mol Cell 2005, 18, 565-576., van der Horst et al., Nat Cell Biol. 2006, 8, 1064-1073).
- the present invention concerns a compound of formula (I):
- i is an integer chosen from 0, 1, 2 or 3 when n is 1, or from 0, 1, 2, 3 or 4 when n is 2, or from 0, 1, 2, 3, 4 or 5 when n is 3;
- j is an integer chosen from 0, 1, 2 or 3;
- k is an integer chosen from 0 or 1;
- n and n′ identical or different are integers chosen from 0, 1, 2 or 4, provided that 2 ⁇ n+n′ ⁇ 4;
- Z is CH 2 ⁇ , —HC ⁇ , —N ⁇ , NH ⁇ or O ⁇ ;
- each Ri located on any available position of the A ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, CF 3 , COR, COOR, CONRR′;
- each Rj located on any available position of the C ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, COR, COOR, CONRR′;
- Rk is independently chosen from halogen, alkyl, alkoxy, cyano
- X is chosen from H, alkyl, aryl, -alkylaryl, wherein said alkyl and/or aryl is optionally substituted by halogen, alkyl, CN, CF 3 , OR, NRR′, COR, COOR, CONRR′;
- Y is chosen from:
- compounds of the invention may be of the following formula:
- Hal is chosen from F, Cl, Br or I.
- X is chosen from H, alkyl optionally substituted by CN;
- Y is as defined above;
- the A ring is chosen from:
- n′ is 0, 1 or 2 and n is 3, 2 or 1.
- n′ is 1 and n is 2.
- A is
- Hal is F, Br or I.
- X is defined as above and Y is chosen from:
- X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
- X is defined as above and Y is chosen from:
- X is chosen from H, alkyl, aryl, -alkylaryl, wherein said alkyl and/or aryl is optionally substituted by halogen, alkyl, CN, CF 3 , OR, NRR′, COR, COOR, CONRR′;
- Y is chosen from:
- compounds of the invention may be of the following formula
- each Ri located on any available position of the A ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, CF 3 , COR, COOR, CONRR′;
- each Rj located on any available position of the C ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, COR, COOR, CONRR′;
- Y is chosen from:
- T is identical or different is independently chosen from H or alkyl and R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl; preferably alkyl;
- those compounds of formula (I) are chosen from:
- the invention concerns the following compounds:
- the invention concerns the following compounds:
- Alkyl means an aliphatic hydrocarbon group which may be straight or branched having 1 to 20 carbon atoms in the chain. Preferred alkyl groups have 1 to 12 carbon atoms in the chain. “Branched” means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl.
- cycloalkyl refers to an aromatic or non aromatic hydrocarbon mono, bi or multi cyclic ring of 3 to 10 carbon atoms formed by the removal of one hydrogen atom.
- a designation such as “C 5 -C 7 cycloalkyl” refers to a cycloalkyl radical containing from 5 to 7 carbon atoms. Examples include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, etc. as well as the systems formed by their condensation or by the condensation with a phenyl group.
- Alken means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having 2 to 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to 12 carbon atoms in the chain; and more preferably about 2 to 4 carbon atoms in the chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, nonenyl, decenyl.
- Perhalogenoalkyl refers to an alkyl group as defined above where all H atoms are replaced by halogen atoms.
- Polyhalogenoalkyl refers to an alkyl group as defined above where one or more H atoms are replaced by halogen atoms.
- Aryl means an aromatic monocyclic or multicyclic hydrocarbon ring system of 6 to 14 carbon atoms, preferably of 6 to 10 carbon atoms.
- exemplary aryl groups include phenyl or naphthyl.
- heterocycle or “heterocyclic” refer to a saturated, partially unsaturated or unsaturated, non aromatic stable 3 to 14, preferably 5 to 10-membered mono, bi or multicyclic rings wherein at least one member of the ring is a hetero atom.
- heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms.
- Preferable heteroatoms are oxygen, nitrogen and sulfur.
- Suitable heterocycles are also disclosed in The Handbook of Chemistry and Physics, 76 th Edition, CRC Press, Inc., 1995-1996, p. 2-25 to 2-26, the disclosure of which is hereby incorporated by reference.
- Preferred non aromatic heterocyclic include, but are not limited to pyrrolidinyl, pyrazolidinyl, irriidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydro-pyranyl, dioxanyl, dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydrothiopyranyl, dithianyl, thiomorpholinyl, dihydro-pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydro-pyridyl, dihydropyridyl, tetrahydropyrimidinyl, dihydrothiopyranyl, azepanyl, as well as the fused systems resulting from the condensation
- heteroaryl refers to a 5 to 14, preferably 5 to 10-membered aromatic hetero, mono-, bi- or multicyclic ring.
- examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, as well as the fused systems resulting from the condensation with a
- Alkyl alkenyl, “cycloalkyl”, “aryl”, “heteroaryl”, “heterocycle” and the likes refers also to the corresponding “alkylene”, “alkenylene”, “cycloalkylene”, “arylene”, “heteroarylene”, “heterocyclene” and the likes which are formed by the removal of two hydrogen atoms.
- the term “patient” refers to either an animal, such as a valuable animal for breeding, company or preservation purposes, or preferably a human or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
- a “therapeutically effective amount” refers to an amount of a compound of the present invention which is effective in preventing, reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions.
- controlling is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment.
- the expression “pharmaceutically acceptable” refers to those compounds, materials, excipients, compositions or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problem complications commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, including mono, di or tri-salts thereof; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucoronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, lactic and the like.
- Further addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
- non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 20 th ed., Mack Publishing Company, Easton, Pa., 2000, the disclosure of which is hereby incorporated by reference.
- the present invention is also concerned with the process of preparation of the compounds of formula (I).
- the compounds and process of the present invention may be prepared in a number of ways well-known to those skilled in the art.
- the compounds can be synthesized, for example, by application or adaptation of the methods described below, or variations thereon as appreciated by the skilled artisan.
- the appropriate modifications and substitutions will be readily apparent and well known or readily obtainable from the scientific literature to those skilled in the art.
- the compounds of the present invention may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms.
- optically active or racemic forms all chiral, diastereomeric, racemic forms, isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
- mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
- Some reactions may be carried out in the presence of a base.
- a base There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used in reactions of this type may equally be used here, provided that it has no adverse effect on other parts of the molecule.
- suitable bases include: sodium hydroxide, potassium carbonate, triethylamine, alkali metal hydrides, such as sodium hydride and potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali metal alkoxides, such as sodium methoxide and sodium ethoxide.
- Suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, such as dimethylformamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran.
- hydrocarbons which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene
- amides such as dimethylformamide
- alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran.
- the reactions can take place over a wide range of temperatures. In general, it is found convenient to carry out the reaction at a temperature of from 0° C. to 150° C. (more preferably from about room temperature to 100° C.).
- the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 20 hours will usually suffice.
- the compound thus prepared may be recovered from the reaction mixture by conventional means.
- the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary, after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract.
- the product can, if desired, be further purified by various well-known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography.
- a compound of the invention of formula (I) can be obtained by reacting a corresponding compound of formula (VII):
- R is OH or a halogen and X′ and Y′ are identical to X and Y respectively, or a precursor thereof, or an amino protecting group, optionally followed by alkylation(s) or deprotection as the case may be, respectively.
- Rk is introduced via convenient functionalization of the keto group which include halogenations, reduction then dehydration, nucleophilic addition followed by dehydration.
- this functionalization comprises the steps of halogenations, reduction then deshydratation.
- the present invention also concerns compound of formula (VI):
- the compound of formula (VI) may be obtained by coupling compounds (II) and (III) or (IV) and (V) according to either of the two pathways below.
- ketones (II) or substituted ketones (IV) are performed with a substituted aniline (III) or (V) leading to the tricyclic acids (VI).
- Amino terephthalic acids (III) or (V) and the corresponding ketones (II) (pathway I) or (IV) (pathway II) are mixed and stirred in the appropriate solvent. Depending on the reactivity, mixture can be heated or catalysed by the use of acidic conditions.
- pathway (II) the reaction is performed via the cyclisation of an intermediate enamine of (IV) and (V).
- —NXY is a diamine. It include the coupling of compounds (VII) with mono-protected—secondary or primary—amines precursor followed by deprotection and one or two successive alkylations using electrophilic reagents such as halides derivatives or aldehydes.
- precursor is used herein to refer to compounds which differ from the indicated or desired compounds by the presence and/or absence of groups or functions. Such groups or functions may be introduced, transformed and/or omitted by common functionalization reactions, known from the skilled person.
- the functionalization reaction may be carried out by application or adaptation of known methods.
- process of the invention may also comprise the additional step of isolating the compound of formula (I). This can be done by the skilled person by any of the known conventional means, such as the recovery methods described above.
- the starting products (II), (III), (IIV), (V) and (VIII) are commercially available mainly from Aldrich or Acros or other typical chemicals supplier or may be obtained by applying or adapting any known methods or those described in the examples.
- the present invention concerns also the pharmaceutical compositions comprising a compound of formula (I) as defined above or a tautomer thereof and/or its pharmaceutically acceptable salts, with a pharmaceutically acceptable excipient.
- the present invention concerns a compound of formula (I) of the invention for inhibiting cysteine protease.
- the compounds of the invention are useful for inhibiting cysteine proteases, in particular specific de-ubiquitination enzymes such as USPs, and more particularly USP-7 in patients in the need thereof.
- the compounds of the invention are particularly useful for treating and/or preventing cancer and metastasis, more particularly prostate and/or colon cancers, neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, immunological disorders, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, viral infections and diseases, and/or viral infectivity and/or latency, bacterial infections and diseases.
- neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, immunological disorders, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, viral infections and diseases, and/or viral infectivity and/or latency, bacterial infections and diseases.
- said viral infections and diseases are chosen from herpes simplex-1 or -2 viral infections, hepatitis A, hepatitis C, SARS coronavirus infection and disease, Epstein-Barr virus, rhinoviral infections and diseases, adenoviral infections and diseases, poliomyelitis.
- said compounds inhibit one or more viral cysteine proteases.
- Bacterial cysteine proteases may be chosen from streptopain, clostripain, staphylococcal cysteine protease, gingipain.
- the present invention also concerns the combinations comprising a compound of formula (I) as defined in anyone of claims 1 to 8 or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof,
- active agents chosen from anti-cancer agents, neurological agents, thrombolytic agents, antioxidant agents. anti-infective, anti-hypertensive agents, diuretic agents, thrombolytic agents, immunosuppressive agents, cardiovascular agents, immunomodulatory agents, anti-inflammatory agents, antiviral agents, anti-bacterial agents.
- the present invention also concerns the corresponding methods of treatment comprising the administration of a compound of the invention together with a pharmaceutically acceptable carrier or excipient to a patient in the need thereof.
- a therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances.
- determining the therapeutically effective amount a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
- the amount of a compound of formula (I), which is required to achieve the desired biological effect will vary depending upon a number of factors, including the chemical characteristics (e.g. hydrophobicity) of the compounds employed, the potency of the compounds, the type of disease, the species to which the patient belongs, the diseased state of the patient, the route of administration, the bioavailability of the compound by the chosen route, all factors which dictate the required dose amounts, delivery and regimen to be administered.
- chemical characteristics e.g. hydrophobicity
- “Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
- “pharmaceutically acceptable excipient” includes any carriers, diluents, adjuvants, or vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- preserving or antioxidant agents such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the use of such media and agents for pharmaceutical active substances is well-known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions as suitable therapeutic combinations.
- treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
- “Therapeutically effective amount” means an amount of a compound/medicament according to the present invention effective in preventing or treating a pathological condition requiring the inhibition of an active cysteine protease involved in its pathogenesis.
- the terms “patient” or “patient in need thereof”, are intended for an animal or a human being affected or likely to be affected with a pathological condition involving an active cysteine protease in its pathogenesis.
- the patient is human.
- the compounds of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v compound for parenteral administration.
- Typical dose ranges are from 1 ⁇ g/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 100 mg/kg of body weight per day or an equivalent dose in a human child.
- the preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the route of administration (intravenous, intramuscular, or other), the pharmacokinetic properties of the compound by the chosen delivery route, and the speed (bolus or continuous infusion) and schedule of administrations (number of repetitions in a given period of time).
- unit dose means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.
- typical total daily dose ranges are from 0.01 to 100 mg/kg of body weight.
- unit doses for humans range from 1 mg to 3000 mg per day.
- the unit dose range is from 1 to 500 mg administered one to six times a day, and even more preferably from 10 mg to 500 mg, once a day.
- compositions can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
- unit dose compositions may be prepared for use by oral administration, particularly in the form of tablets, simple capsules or soft gel capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, for example, topically in ointments, creams, lotions, gels or sprays, or via trans-dermal patches.
- compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20 th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2000.
- Preferred formulations include pharmaceutical compositions in which a compound of the present invention is formulated for oral or parenteral administration.
- tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate.
- a binder such as microcrystalline cellulose, or gum tragacanth
- a diluent such as starch or lactose
- a disintegrant such as starch and cellulose derivatives
- a lubricant such as magnesium stearate
- a glidant such as colloidal silicon dioxide
- a sweetening agent such as sucrose or saccharin
- a flavoring agent such
- Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule.
- dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
- Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings.
- the active compounds may be incorporated into fast dissolve, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal.
- Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination.
- Liquid preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- the liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like.
- Non-aqueous solvents include alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl oleate.
- Aqueous carriers include mixtures of alcohols and water, buffered media, and saline.
- biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds.
- Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like.
- Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
- formulations for inhalation which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
- Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
- Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
- Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
- Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations.
- Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
- Representative compounds of the invention can be synthesized according to the following procedures.
- LC-MS analysis was used to analyze and purify target compounds.
- LC-MS analyses were performed using an Waters Micromass, Bruker Esquire 3000 (ESI-IT) or Agilent Iontrap XCT-Plus mass spectrometers and Waters Alliance 2790 or Agilent 1100 Series LC systems with UV and/or DAD detection.
- Potassium permanganate was dissolved in water (400 mL) in a flask fitted with a thermometer and a reflux condenser. 4-Nitro-m-xylene was added. The mixture was cautiously heated to 85° C.
- reaction mixture was cooled to 25° C., product was filtered, washed with pentane and then with MeOH, dried under vacuum to get the pure desired product as a beige solid (700 mg, 63%).
- reaction mixture was cooled to 25° C., diluted with ethyl acetate and filtered through celite. Filtrate was concentrated and purified by silica gel (60:120) column. Product eluted with 10% ethyl acetate in ether. Fractions were collected and concentrated to get the product as off while solid with 70% purity. The product was further purified by preparative HPLC.
- the cDNA encoding USP7 was obtained by PCR amplification from placenta mRNA. USP7 cDNA was subcloned by PCR into a baculovirus expression vector (pFastBac-HT; Invitrogen). Full-length wild-type human USP7 and its catalytic mutant (cysteine 223 replaced by alanine, C223A) were produced as N-terminally His-tagged fusions in Spodoptera frugiperda cells (Sf9, Invitrogen), using the Bac-to-Bac Baculovirus system from Invitrogen according to the manufacturer's instructions.
- pFastBac-HT-B-USP7 was used to transform DH10bac cells (Invitrogen), and blue/white selection was carried out on X-gal/IPTG agar plates.
- Bacmid DNA was prepared by an alkaline lysis procedure. The integrity of the bacmid minipreps and their orientation were checked by PCR, using generic and specific primers.
- Sf9 insect cells were cultured in InsectXpress medium (Cambrex) at 27° C. and transfected with the corresponding bacmid, using GeneShuttle 40 (Q-BIOgen). Viruses were recovered in the supernatant 72 h after transfection.
- Viruses were amplified by infecting insect cells (Sf9 or High Five cells; invitrogen) in 50 ml InsectXpress medium in a 150 cm 2 cell culture flask with 500 ⁇ l of the supernatant from transfected Sf9 cells. Following the second round of amplification, infected cells were recovered by rapid SDS lysis, boiled for 5 min at 100° C., sonicated briefly and centrifuged for 20 min at 14,000 g. Expression levels in infected Sf9 cells were compared with those in uninfected cells. Fusion proteins were then allowed to bind to TALON beads (BD Biosciences, TALON metal affinity resin) for 30 min at 4° C. with gentle rocking.
- TALON beads BD Biosciences, TALON metal affinity resin
- Fractions containing high concentrations of purified proteins (purity >95%) were dialyzed (20 mM Tris HCl pH 7.6, 200 mM NaCl, 1 mM DTT, 1 mM EDTA and 10% glycerol) were aliquoted and snap frozen in liquid nitrogen before storage at ⁇ 80° C.
- USP7 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01° AD Triton X-100; Bovine Serum Albumin 0.05 mg ⁇ ml ⁇ 1 pH7.6).
- Compounds stocks (10 mM) were stored at ⁇ 20° C. in DMSO.
- Compounds were tested at different concentrations: from 200 ⁇ M to 91 nM.
- USP5 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg ⁇ ml ⁇ 1 pH 7.6).
- Compounds stocks (100 mM) were stored at ⁇ 20° C. in DMSO. Compounds were tested at different concentrations: from 2000A to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 ⁇ l final reaction volume).
- the substrate concentration for USP5 was 300 nM Ub-AMC (Boston Biochem).
- the concentrations of the enzyme (USP5) in specificity assays was 300 pM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration.
- Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/ ⁇ compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final).
- the cDNA encoding USP8 was obtained by PCR amplification from placenta mRNA. USP8 cDNA was subcloned by PCR into a baculovirus expression vector (pFastBac-HT; Invitrogen). A cDNA encoding a mutated USP8 was generated by mutagenic PCR. The corresponding protein encodes a cysteine to alanine substitution at residue 786. The sequences were ascertained by sequencing of the entire open reading frame. Bacmids encoding USP8 were generated following DH10bac transposition. The corresponding bacmids were transfected into insect cells (Sf9). Viruses were recovered from culture supernatant and amplified twice.
- Insect cells (Sf9 or High Five; Invitrogen) were infected for 72 hours. Total cell lysates were harvested and lyzed in lysis buffer (Tris HCl 50 mM pH7.6; 0.75% NP40; 500 mM NaCl; 10% glycerol; 1 mM DTT; 10 mM imidazole; Protease Inhibitor Cocktail; AEBSF 20 ⁇ g ⁇ ml ⁇ 1 ; Aprotinin 10 ⁇ g ⁇ ml ⁇ 1 ). Proteins were affinity purified on metal affinity resins (Talon Metal affinity resin; BD Biosciences).
- Bound materials were extensively washed in wash buffer (50 mM Sodium Phosphate pH 7.0; 300 mM NaCl; 10 mM imidazole; 0.5% Triton X-100; 10% glycerol) and eluted from the resin in 250 mM imidazole-containing wash buffer. Proteins were dialyzed in dialysis buffer (Tris HCl pH 7.6 20 mM; NaCl 200 mM; DTT 1 mM; EDTA 1 mM; 10% Glycerol). Proteins purifications were analyzed on 4-12% NuPAGE (Invitrogen).
- USP8 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg ⁇ ml ⁇ 1 pH8.8).
- Compounds stocks (100 mM) were stored at ⁇ 20° C. in DMSO. Compounds were tested at different concentrations: from 200 ⁇ M to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 ⁇ l final reaction volume).
- the substrate concentration for USP8 was 300 nM Ub-AMC (Boston Biochem).
- the concentration of the enzyme (USP8) in specificity assays was 1.36 nM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration. Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/ ⁇ compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final).
- UCH-L1 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg ⁇ ml ⁇ 1 pH7.6).
- Compounds stocks (100 mM) were stored at ⁇ 20° C. in DMSO.
- Compounds were tested at different concentrations: from 200 ⁇ M to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 ⁇ l final reaction volume).
- the substrate concentration for UCH-L1 was 300 nM Ub-AMC (Boston Biochem).
- the concentration of the enzyme (UCH-L1) in specificity assays was 2.5 nM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration.
- Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/ ⁇ compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final).
- UCH-L3 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg ⁇ ml ⁇ 1 pH7.6).
- Compounds stocks (100 mM) were stored at ⁇ 20° C. in DMSO.
- Compounds were tested at different concentrations: from 200 ⁇ M to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 ⁇ l final reaction volume).
- the substrate concentration for UCH-L3 was 300 nM Ub-AMC (Boston Biochem).
- the concentration of the enzyme (UCH-L3) in specificity assays was 13 pM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration.
- Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/ ⁇ compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final).
- Caspase 3 was diluted in Caspase 3 buffer (100 mM Hepes pH 7.5; 10% sucrose; 0.1% CHAPS). Compounds stocks (100 mM) were stored at ⁇ 20° C. in DMSO. Compounds were tested at different concentrations: from 200 ⁇ M to 91 nM.
- HCT116 colon cancer cells were obtained from ATCC (American Type Culture Collection), and maintained in Mc Coy's 5A medium containing 10% FBS, 3 mM glutamine and 1% penicillin/streptomycin. Cells were incubated at 37° C. in a humidified atmosphere containing 5% CO 2 .
- MTS 3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-zolium
- MTT-derived tetrazolium is a MTT-derived tetrazolium that is reduced in metabolically active cells into a soluble, cell-permeant formazan.
- the amount of formazan, detected by its absorbance at 492 nm is proportional to the number of living, metabolically active cells.
- This tool which binds covalently to the cysteine active site of deubiquitinating enzymes, was successfully applied to discover and characterize novel ubiquitin/ubiquitin-like proteases and to profile active deubiquitinating enzymes in normal, virus-infected, and malignant cells (Borodovsky et al., Chem Biol 2002, 9, 1149-1159, Hemelaar et al., Mol Cell Biol 2004, 24, 84-95, Ovaa et al., Proc Natl Acad Sci USA 2004 101, 2253-2258).
- the HA-Ub-VS probe Hemagglutin tag-Ubiquitin-Vinyl Sulfone was used in this study to directly visualize the activity of all deubiquitinating enzymes from cell lysates. This tool was used to evaluate the activity/specificity of our small molecule compounds on USP7 relative to all deubiquitinating enzymes active in physiological conditions.
- the C-terminally modified vinyl sulfone derivative of ubiquitin (HA-Ub-VS), binds covalently to the cysteine active site of deubiquitinating enzymes.
- This labeling followed by immunoblot with the anti-HA antibody allowed the identification of all active deubiquitinating enzymes from HCT116 cell lysates ( FIG. 1B ).
- active USP7 was identified in this assay as indicated by the mobility shift observed following immunoblot with anti-USP7 antibody.
- This labeling, specific to the active form of DUBs is inhibited by a thiol-reactive compound (NEM) in a non-specific manner ( FIG. 1B ).
- NEM thiol-reactive compound
- HCT116 cells were next treated either with different doses of compounds of examples 14 and 5 or with Doxycycline to induce USP7 silencing. Localization of the HA-Ub-VS-USP7 protein was facilitated by the specific silencing of USP7 as indicated in the presence of doxycycline ( FIG. 4A , +Dox). Once this band identified, cell lysates were treated with different doses of compounds of examples 14 and 5 and a specific and dose-dependent decrease of the HA-Ub-VS-USP7 protein level was clearly observed ( FIGS. 4A and B). This effect on USP7 activity was confirmed with anti-USP7 antibody as indicated by the mobility shift observed between the treated and non-treated samples.
- a cDNA encoding the fusion protein between ubiquitin and the ribosomal protein L40 was amplified from human RNA using a proprietary human placenta library.
- the cDNA was subcloned into a bacterial expression vector (pGEX-2T, GE Healthcare), including an additional flag tag at the carboxyl end of the encoded protein.
- the following primers were used for subcloning in frame with the GST tag the ubiquitin-L40 into pGEX-2T: 5′-cgtggatccatgcagatctttgtgaagaccctc-3′ (SEQ ID NO:10) and 5′-gcgaattctttatcgtcatcgtctttgtagtctttgaccttcttcttgggacg-3′ (SEQ ID NO:11) into BamHI & EcoRI restriction sites.
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- the present examples 26 to 38 makes it possible to validate the use of GST-Ub52-Flag in an assay based on the time-resolved measurement of fluorescence emitted by radioactive transfer in homogenous medium.
- the assay is carried out on multiwell assay plates.
- the plates are analyzed on a PHERAstar fluorimeter (BMG) after an overnight incubation at 4° C. (excitation 337 nm, emission 620 and 665 nm).
- the enzyme reaction is carried out by mixing GST-Ub52-flag solution with 5 ⁇ l of USP7 solution (200 pM final) or 5 ⁇ l of USP8 (400 pM final). This mixture is incubated for one hour at room temperature on a multiwell assay plate. A 10 ⁇ l mixture of 5 ⁇ l of anti-Flag-K solution (0.2 ⁇ M) plus 5 ⁇ l of anti-GST-XL665 antibody (2.6 ⁇ M) is added to each well of the multiwell assay plate. The plate is read after an overnight incubation at 4° C. on a PHERAstar fluorimeter (BMG).
- BMG PHERAstar fluorimeter
- the decrease in the signal correlates with the increase in enzyme activity i.e. the cleavage of GST-Ub52-Flag substrate.
- the format used is therefore entirely suitable for a method of assaying an enzyme of the deubiquitinating type such as ubiquitin specific protease, but also for determining a modulator of this enzyme activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Abstract
The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
Description
- The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
- Ubiquitin specific proteases (USP) are cysteines proteases which belong to the deubiquitinylation enzymes (DUBs) family.
- Deregulation of the ubiquitin-proteasome system has been implicated in the pathogenesis of many human diseases, including cancer (Hoeller et al. Nat Rev Cancer 2006, 6(10), 776-788), neurodegenerative disorders (Rubinsztein, Nature 2006, 443(7113), 780-786) and viral diseases (Gao & Luo Can J Physiol Pharmacol 2006, 84(1), 5-14). The market success of the proteasome inhibitor Velcade® (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma has established this system as a valid target for cancer treatment (Adams, Nat Rev Cancer 2004, 4(5), 349-360). A promising alternative to targeting the proteasome itself would be to interfere with the upstream ubiquitin conjugation/deconjugation machinery, to generate more specific, less toxic anticancer agents.
- Mono- and polyubiquitination can be reversed by deubiquitinating enzymes, which specifically cleave the isopeptide bond at the C-terminus of ubiquitin. Ubiquitin specific proteases and ubiquitin C-terminal hydrolases (UCH) enzymes are the best characterized members of the DUB family (Komander et al. Nat. Rev. Mol. Cell Biol. 2009, 10(8), 550-63; Nijman et al. Cell 2005, 123(5), 773-786). UCHs are thought to cleave small protein substrates preferentially and to be involved principally in the processing and recycling of ubiquitin, but their specific functions remain poorly understood. USPs constitute the largest subfamily of DUBs, with more than 60 members. They remove ubiquitin from specific protein substrates, thus preventing their targeting to the proteasome or regulating their subcellular localization and activation (Daviet & Colland, Biochimie 2008, 90(2), 270-83). USPs are emerging as potential targets for pharmacological interference with the ubiquitin regulation machinery, based on their protease activity and involvement in several human diseases.
- USP7 (Ubiquitin Specific Protease 7)/HAUSP (Herpes Associated Ubiquitin Specific Protease) is a 135 kDa protein of the USP family. USP7 has been shown to interact with viral proteins, such as ICP0 (Vmw 11.0), a herpes simplex virus immediate-early gene stimulating initiation of the viral lytic cycle (Everett et al., J Virol 73, 1999, 417-426), and EBNA1 (Epstein-Barr Nuclear Antigen-1) (Holowaty et al., J Biol Chem 2003, 278, 29987-29994 and 47753-47761). Human proteins, such as p53 and the major E3 ligase of p53, Mdm2, have also been identified as partners and substrates of USP7 (Cummins et al. Nature 2004, 486, Cummins & Vogelstein, Cell Cycle, 2004, 3, 689-692; Li et al. Mol Cell 2004, 13, 879-886; Li et al. Nature 2002, 416, 648-653). More generally USP7 can deubiquitinate different targets, including Mdm2 and p53, and the net deubiquitination of these latter targets ultimately determines functional p53 levels. Consistent with recent reports, USP7 silencing has also been shown to increase steady-state p53 levels by promoting Mdm2 degradation. Binding of USP7 to p53 was recently shown to be regulated by TSPYL5, a protein potentially involved in breast oncogenesis through a competition with p53 for binding to the same region of USP7 (Epping et al., Nat Cell Biol. 2011, 13(1):102-8). More recently, both upregulation and downregulation of USP7 have been shown to inhibit colon cancer cell proliferation in vitro and tumor growth in vivo, by resulting in constitutively high p53 levels (Becker et al. Cell Cycle 2008, 7(9), 1205-13).
- USP7 also alters the level of the p16INK4a tumor suppressor through Bmi1/Mel18 stabilization (Maertens et al., Embo J. 2010 29, 2553-2565). Additional proteins involved in genomic integrity/regulation such as the DNMT1 DNA methylase and the Claspin adaptor are also stabilized by USP7 (Du et al., Science Signaling 2010, 3(146):ra80; Faustrup et al., J. Cell Biol. 2009, 184(1):13-9). Importantly, the abundance of USP7 and DNMT1, a protein involved in maintaining epigenetic methylation required to silence genes involved in development and cancer, correlates in human colon cancer (Du et al, Science Signaling, 2010, 3(146):ra80). USP7 has also been shown in human cells to deubiquitinate the well-known tumor suppressor gene PTEN, which provokes its nuclear export and hence its inactivation (Song et al., Nature 2008, 455(7214), 813-7). More importantly, USP7 overexpression was reported for the first time in prostate cancer and this overexpression was directly associated with tumour aggressiveness (Song et al., Nature 2008, 455(7214), 813-7).
- USP7 has also been shown in human cells to deubiquitinate FOXO4, which provokes its nuclear export and hence its inactivation; consequently the oncogenic PI3K/PKB signaling pathway was activated (van der Horst et al., Nat Cell Biol. 2006, 8, 1064-1073) Finally, USP7 plays an important role in p53-mediated cellular responses to various types of stress, such as DNA damage and oxidative stress (Marchenko et al., Embo J. 2007 26, 923-934, Meulmeester at al. Mol Cell 2005, 18, 565-576., van der Horst et al., Nat Cell Biol. 2006, 8, 1064-1073).
- Synthetic inhibitors of USP7 protein binding containing the polypeptide portion P1-Gly-P3-Ser, where P1 is a glutamic acid residue or an amino acid with a non polar side chain and P3 is a glycine residue or an amino acid with non polar side chain, have been reported (WO2006072048).
- The phenotypes associated with USP7 silencing and the known connections between USP7 and essential viral proteins and oncogenic pathways, such as the p53/Mdm2 and PI3K/PKB pathways, strongly suggest that targeting USP7 with small-molecule inhibitors may be beneficial in the treatment of cancers and viral diseases. An inhibitor against USP7 was recently reported (Colland et al. Molecular Cancer Therapeutics 2009, 8, 2286-95 and EP 1 749 822).
- However, to date, no specific USP7 small molecule inhibitors seem to have been reported.
- According to a first object, the present invention concerns a compound of formula (I):
-
- wherein:
- i is an integer chosen from 0, 1, 2 or 3 when n is 1, or from 0, 1, 2, 3 or 4 when n is 2, or from 0, 1, 2, 3, 4 or 5 when n is 3;
- j is an integer chosen from 0, 1, 2 or 3;
- k is an integer chosen from 0 or 1;
- n and n′ identical or different are integers chosen from 0, 1, 2 or 4, provided that 2≦n+n′≦4;
- Z is CH2<, —HC<, —N<, NH< or O<;
- each Ri located on any available position of the A ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, CF3, COR, COOR, CONRR′;
- each Rj located on any available position of the C ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, COR, COOR, CONRR′;
- Rk is independently chosen from halogen, alkyl, alkoxy, cyano;
- X is chosen from H, alkyl, aryl, -alkylaryl, wherein said alkyl and/or aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
- Y is chosen from:
-
- (CT2′)pNRaRb where
- Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl or arylalkyl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, ═O, OR, NRR′, COR, COOR, CONRR′;
- or Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; CN; CF3; OR; NRR′; COR; COOR; CONRR′; said heterocycle being optionally fused with an aryl;
- p is an integer chosen from 0 to 6;
- each T′, identical or different is independently chosen from H or a linear or branched alkyl wherein the alkyl is optionally substituted by one or more OR, aryl; in one embodiment at least one of T′ is different from H;
- (CT2′)pNRaRb where
-
-
- wherein:
-
-
-
- is a saturated or partially unsaturated heterocycle or heteroaryl, mono or bicyclic, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; -alkylaryl; OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl or -alkylaryl wherein said aryl is optionally substituted by a linear or branched alkyl, halogen, OR, COR or NR′R;
- q is an integer chosen from 0 to 6;
- each T, identical or different is independently chosen from H or alkyl;
- is a saturated or partially unsaturated heterocycle or heteroaryl, mono or bicyclic, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; -alkylaryl; OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl or -alkylaryl wherein said aryl is optionally substituted by a linear or branched alkyl, halogen, OR, COR or NR′R;
- (CHT)r-aryl wherein:
- said mono or bicyclic aryl is optionally substituted by one or more of alkyl; OR; CF3, SO2NRR′; —C(═O)—R; Halogen; CN; —NRR′; CONRR; C(═O)—Oalkyl wherein said alkyl is optionally substituted by NRR′ or NR″R′″; and/or said mono or bicyclic aryl is optionally fused with a monocyclic 5 to 7 membered heterocycle;
- r is an integer chosen from 0 to 6;
- each T, identical or different is independently chosen from H or alkyl;
where R″ and R′″ together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; CN; CF3; OR; NRR′; COR; COOR; CONRR′;
- (CHT)s-(C3-C7)cycloalkyl where
- s is an integer chosen from 0 to 6;
- each T, identical or different is independently chosen from H or alkyl;
- said cycloalkyl is monocyclic, or fused with an aryl;
- alkyl optionally substituted by CN, Oalkyl;
- U—S(O)t-alkyl where
- t is an integer chosen from 0, 1 or 2;
- —U— is an alkylene optionally substituted by one or more of OR; ═O; CF3, SO2NRR′; —C(═O)—R; Halogen; CN; —NRR′; CONRR; C(═O)OR;
-
- or X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
-
- being optionally substituted by one or more of: ═O; Hal, CN, NRR′, C(═O)alkyl, alkyl; cycloalkyl; heterocycle; C(═O)—Oalkyl; -alkylheterocycle; aryl or -alkylaryl where said aryl is optionally fused with an heterocycle and/or said aryl being optionally substituted by alkyl or COalkyl; said heterocycle being optionally substituted by an alkyl;
- being optionally fused with an aryl;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl,
or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof.
- The formula (I) of the invention refers to any of the following embodiment or any of their combinations.
- According to a particular embodiment, formula (I) does not encompass those compounds where Hal is Cl, i=j=0, and
- n′=1, n=1, X is H or a C1-2alkyl and Y is a phenyl optionally substituted by one or two C1-C2alkyl, or
- n′=1, n=2, and:
-
- X is H and Y is a phenyl substituted by CN or —C(═O)CH3; or
- X and Y together form a piperazinyl ring substituted by a methoxyphenyl or fluorophenyl; or
- X and Y together form a piperidyl ring substituted by a piperidyl; or
- one of X is H and Y is a piperidyl substituted with COOEt.
- In particular, compounds of the invention may be of the following formula:
- where Hal is chosen from F, Cl, Br or I.
- Particular compounds are those of formula (I), wherein:
- i=j=0; and/or
- X is chosen from H, alkyl optionally substituted by CN;
- Y is as defined above;
- or X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
-
- being optionally substituted by one or more of: ═O; Hal, CN, NRR′, C(═O)alkyl, alkyl; cycloalkyl; heterocycle; C(═O)—Oalkyl; -alkylheterocycle; aryl or -alkylaryl where said aryl is optionally fused with an heterocycle and/or said aryl being optionally substituted by alkyl or COalkyl; said heterocycle being optionally substituted by an alkyl;
- being optionally fused with an aryl.
- In particular, the A ring is chosen from:
- Preferably, n′ is 0, 1 or 2 and n is 3, 2 or 1.
- In particular, in formula (I), n′ is 1 and n is 2.
- More preferably A is
- According to an embodiment, Hal is F, Br or I.
- According to a further embodiment:
- X is defined as above and Y is chosen from:
-
- (CT2′)pNRaRb where
- Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl, -alkylaryl, wherein said aryl is optionally substituted by alkyl;
- p is 0 to 4.
- or where
- Ra and Rb together form with the N atom to which they are attached a 5 to 7-membered heterocycle optionally comprising one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl where aryl is optionally substituted by halogen; ═O; CN; CF3; OR; NRR′; COR; COOR; CONRR′; said heterocycle being optionally fused with an aryl and;
- p is chosen from 2 or 3;
- each T′, identical or different, is independently chosen from H or a linear or branched alkyl, wherein the alkyl is optionally substituted by one or more OR, aryl; in one embodiment at least one of T′ is different from H;
- (CT2′)pNRaRb where
-
- wherein:
-
- is a bicyclic saturated or partially unsaturated heterocycle or heteroaryl, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; OR; C(═O)OR; aryl or -alkylaryl wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R;
- q is an integer chosen from 0, 1, 2 or 3;
- each T, identical or different is independently chosen from H or alkyl;
- (CHT)r-aryl wherein:
- said aryl is mono or bicyclic, optionally substituted by one or more of alkyl, OR, SO2NRR′; —C(═O)—R; Halogen; CN; C(═O)—Oalkyl, wherein said alkyl is optionally substituted by NRR′ or NR″R′″; and said aryl is optionally fused with an heterocycle;
- r is an integer chosen from 0, 1, 2 or 3;
- each T, identical or different is independently chosen from H or alkyl;
or
- is a bicyclic saturated or partially unsaturated heterocycle or heteroaryl, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; OR; C(═O)OR; aryl or -alkylaryl wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R;
- X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
-
- being optionally substituted by one or more of: ═O; alkyl; cycloalkyl; heterocycle; -alkylheterocyle; C(═O)—Oalkyl; aryl or -alkylaryl where said aryl is optionally substituted by alkyl; said heterocycle being optionally substituted by an alkyl;
- being optionally fused with an aryl;
where, preferably, q is 1, 2 or 3, r is 1, 2 or 3.
- More particularly, in formula (I):
- n′=1 and n=2 or 3;
- X is defined as above and Y is chosen from:
-
- (CT2′)pNRaRb where
- Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl, -alkylaryl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
- or Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle optionally comprising one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; ═O; CN; CF3; OR; NRR′; COR; COOR; CONRR′; said heterocycle being optionally fused with an aryl;
- p is an integer chosen from 2 to 3;
- each T′, identical or different is independently chosen from H or a linear or branched alkyl; wherein the alkyl is optionally substituted by one or more OR, aryl; in one embodiment at least one of T′ is different from H; or
- (CT2′)pNRaRb where
-
-
- wherein:
-
-
-
- is saturated or partially unsaturated heterocycle or heteroaryl, mono or bicyclic, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; -alkylaryl; OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R;
- q is 1, 2 or 3;
- each T, identical or different is independently chosen from H or alkyl;
- (CHT)r-aryl wherein:
- said aryl is a monocyclic aryl and is optionally substituted by one or more of alkyl, SO2NRR′; —C(═O)—R; CN; C(═O)—Oalkyl; wherein said alkyl is substituted by NRR′ or NR″R′″;
- r is an integer chosen from 0 to 6;
- each T, identical or different is independently chosen from H or alkyl;
where R″ and R′″ together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; CN; CF3; OR; NRR′; COR; COOR; CONRR′;
-
- or X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
-
- being optionally substituted by one or more of: ═O; alkyl; cycloalkyl; heterocycle; -alkylheterocycle; C(═O)—Oalkyl; -alkylaryl where said aryl is optionally fused with an heterocycle and/or said aryl being optionally substituted by alkyl or COalkyl; said heterocycle comprising one or two nitrogen atom and being optionally substituted by an alkyl;
- being optionally fused with an aryl;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl.
- More preferably in formula (I):
- n′=1, n=2 or 3;
- X is chosen from H, alkyl, aryl, -alkylaryl, wherein said alkyl and/or aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
- and Y is chosen from:
-
- (CT2′)pNRaRb where
- Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl, -alkylaryl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
- p is 1, 2 or 3; or
- Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle wherein the carbon atom adjacent to the heteroatom is optionally substituted by an alkyl; said heterocycle being optionally fused with an aryl;
- p is 3 or 4; or
- Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; CN; CF3; OR; NRR′; COR; COOR; CONRR′;
- p is an integer chosen from 0 to 6;
- each T′, identical or different, is independently chosen from H or a linear or branched alkyl, wherein the alkyl is optionally substituted by one or more OR, aryl, and at least one of T′ is different from H.
- (CHT)r-aryl wherein:
- said aryl is a monocyclic aryl and is optionally substituted by one or more of alkyl, SO2NRR′; —C(═O)—R; CN; C(═O)—Oalkyl; wherein said alkyl is substituted by NRR′ or NR″R′″;
- r is an integer chosen from 0 to 6;
- each T, identical or different is independently chosen from H or alkyl;
- (CT2′)pNRaRb where
-
-
- wherein:
-
-
-
- is a saturated monocyclic five membered heterocycle comprising a nitrogen atom and substituted by an alkyl, provided that the alkyl is not an ethyl, -alkylaryl, OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R; or a monocyclic 6 membered heterocycle comprising an nitrogen atom and optionally substituted by one or more of -alkylaryl, OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by halogen, COR, OR or NR′R;
- q is an integer chosen from 0 to 6;
- each T, identical or different is independently chosen from H or alkyl.
-
- or X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
-
- being optionally substituted by one or more of: ═O; alkyl; cycloalkyl; heterocycle; -alkylheterocycle; C(═O)—Oalkyl; -alkylaryl where said aryl is optionally fused with an heterocycle and/or said aryl being optionally substituted by alkyl or COalkyl; said heterocycle comprising one or two nitrogen atom and being optionally substituted by an alkyl;
- being optionally fused with an aryl;
- In particular, compounds of the invention may be of the following formula
-
- wherein:
- i is an integer chosen from 0, 1, 2, 3 or 4; preferably i=0
- j is an integer chosen from 0, 1, 2 or 3; preferably j=0
- each Ri located on any available position of the A ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, CF3, COR, COOR, CONRR′;
- each Rj located on any available position of the C ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, COR, COOR, CONRR′;
- X is H
- Y is chosen from:
-
- (CHT)r-aryl wherein:
- said aryl is a monocyclic aryl and is optionally substituted by one or more of alkyl, SO2NRR′; —C(═O)—R; CN; —NRR′, CONRR, C(═O)—Oalkyl; wherein said alkyl is substituted by NRR′ or NR″R′″; preferably the aryl is a phenyl substituted by an alkyl substituted by NR″R′″
- r is an integer chosen from 0 to 6; preferably r is 0 or 1;
- each T is H;
where R″ and R″ together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; CN; CF3; OR; NRR′; COR; COOR; CONRR′; preferably R″ and R′″ together form with the N atom to which they are attached a 5-membered heterocycle optionally substituted by one or more of halogen; alkyl; CN; CF3; OR; NRR′; COR; COOR; CONRR′; preferably R″ and R′″ together form with the N atom to which they are attached a 5-membered heterocycle;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl; preferably the aryl is a phenyl substituted by an alkyl substituted by NR″R′″ and R″ and R′″ together form with the N atom to which they are attached a 5-membered heterocycle;
- (CT2′)pNRaRb where
- when each T′ is H,
- Ra and Rb together form with the N atom to which they are attached
- a N comprising 6-membered mono substituted heterocycle wherein the carbon atom adjacent to the heteroatom is substituted by an alkyl; and p is 1, 3 or 4; preferably p is 4 or
- a N-comprising 6-membered heterocycle and p is 1 to 4, preferably p is 1 to 3, for example p is 2; or
- a N-comprising 5-membered heterocycle wherein the carbon atom adjacent to the heteroatom is substituted by an alkyl; and p is 1 to 4, preferably p is 1, 2 or 3; preferably p is 2 or 3; or
- a N-comprising 7-membered heterocycle optionally substituted by an alkyl and p is 1, 2 or 4, preferably p is 2;
- a N-comprising 5-membered heterocycle and p is 1, 2 or 4;
- a N-comprising 5- to 7-membered heterocycle substituted by one or more of halogen, -alkylaryl, or aryl, wherein said aryl is optionally substituted by one or more of halogen, —CN, CF3; OR; NRR′; COR; COOR; CONRR′;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl;
- Ra and Rb together form with the N atom to which they are attached
- Preferably: Ra and Rb together form with the N atom to which they are attached
- a N comprising 6-membered mono substituted heterocycle wherein the carbon atom adjacent to the heteroatom is substituted by an alkyl; and p is 1, 3 or 4; preferably p is 4 or
- a N-comprising 6-membered heterocycle and p is 1 to 4, preferably p is 1 to 3, for example p is 2; or
- a N-comprising 5-membered heterocycle wherein the carbon atom adjacent to the heteroatom is substituted by an alkyl; and p is 1 to 4, preferably p is 1, 2 or 3; preferably p is 2 or 3; or
- a N-comprising 7-membered heterocycle optionally substituted by an alkyl and p is 1, 2 or 4, preferably p is 2;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl,
- when each T′, identical or different, is independently chosen from H or a linear or branched alkyl, wherein the alkyl is optionally substituted by one or more OR, aryl, and at least one of the T′ is different from H,
- Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl or arylalkyl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, ═O, OR, NRR′, COR, COOR, CONRR′; and p is an integer chosen from 0 to 6; preferably Ra and Rb, identical or different, are alkyl and p is 2, 3 or 4, preferably p is 3 or 4; or
- Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; CN; CF3; OR; NRR′; COR; COOR; CONRR′; and p is an integer chosen from 0 to 6; preferably Ra and Rb form with the N atom to which they are attached a N-comprising 5-membered heterocycle and p is 2, 3 or 4;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl,
- (CHT)r-aryl wherein:
- wherein:
- is
-
- a saturated monocyclic 5-membered heterocycle comprising a nitrogen atom and substituted by an alkyl, provided that the alkyl is not an ethyl; -alkylaryl; OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R; or
- a monocyclic 6 membered heterocycle comprising an nitrogen atom and optionally substituted by one or more of -alkylaryl, OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by halogen, COR, OR or NR′R;
- q is an integer chosen from 0 to 6; preferably 0, 1 or 2; preferably 1 or 2;
- each T, identical or different is independently chosen from H or alkyl;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl; preferably alkyl; - preferably
- is a pyrrolidine or a piperidine optionally substituted by methyl, -alkylaryl, where aryl is optionally substituted by halogen, COR, OR or NR′R, preferably by OR or NR′R; q is 1 or 2, T is identical or different is independently chosen from H or alkyl and R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl; preferably alkyl;
-
- or X and Y together form with the N atom to which they are attached an heterocycle, preferably a 6- or 7-membered heterocycle; comprising said N atom and optionally one or two more heteroatoms, preferably one more nitrogen; said heterocyle is optionally insaturated and/or is optionally substituted by one or more heterocycle or -alkylheterocycle said heterocycle, comprising one or two heteroatom, preferably nitrogen, and being optionally substituted by an alkyl;
preferably the heterocycle is a 6-membered heterocycle optionally comprising one more nitrogen, and optionally insaturated and/or optionally substituted by one or more heterocycle; -alkylheterocycle said heterocycle, comprising one or two heteroatom, preferably nitrogen, being optionally substituted by an alkyl; or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof.
- or X and Y together form with the N atom to which they are attached an heterocycle, preferably a 6- or 7-membered heterocycle; comprising said N atom and optionally one or two more heteroatoms, preferably one more nitrogen; said heterocyle is optionally insaturated and/or is optionally substituted by one or more heterocycle or -alkylheterocycle said heterocycle, comprising one or two heteroatom, preferably nitrogen, and being optionally substituted by an alkyl;
- According a specific embodiment, those compounds of formula (I) are chosen from:
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [1-(3-methyl-benzyl)-piperidin-4-ylmethyl]-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-dipropylamino-ethyl)-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [2-(butyl-ethyl-amino)-ethyl]-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(benzyl-ethyl-amino)-propyl]-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-dipropylamino-propyl)-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-diethylamino-ethyl)-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(2,6-dimethyl-piperidin-1-yl)-propyl]-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-diethylamino-propyl)-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-dimethylamino-ethyl)amide
- Azepan-1-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(4-propyl-piperazin-1-yl)-propyl]-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(benzyl-methyl-amino)-propyl]-amide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide
- [1,4′]Bipiperidinyl-1′-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-morpholin-4-yl-propyl)-amide
- 9-chloro-N-(3-(2-methylpiperidin-1-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)phenyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-(4-methoxybenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-4-N,N-dimethylbenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-hydroxy-3-phenyl-2-pyrrolidin-1-ylmethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- N-(2-(azepan-1-yl)ethyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(2-(piperidin-1-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- (9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(4-((1-methylpiperidin-4-yl)methyl)piperazin-1-yl)methanone
- (9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(4-(1-methylpiperidin-4-yl)piperazin-1-yl)methanone
- (9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(piperidin-1-yl)methanone
- N-((1-benzylpiperidin-4-yl)methyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-(3-phenylpropyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-phenethylpiperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(5-(diethylamino)pentan-2-yl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- (R)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- (S)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(dimethylamino)-2,2-dimethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- Chlorhydrate of 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid (2-diethylamino-ethyl)amide
or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof. - Preferably the invention concerns the following compounds:
- 9-chloro-N-(3-(2-methylpiperidin-1-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)phenyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-(4-methoxybenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-4-N,N-dimethylbenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-hydroxy-3-phenyl-2-pyrrolidin-1-ylmethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide
- Azepan-1-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- [1,4′]Bipiperidinyl-1′-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- N-(2-(azepan-1-yl)ethyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(2-(piperidin-1-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(4-((1-methylpiperidin-4-yl)methyl)piperazin-1-yl)methanone
- (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(4-(1-methylpiperidin-4-yl)piperazin-1-yl)methanone
- (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(piperidin-1-yl)methanone
- N-((1-benzylpiperidin-4-yl)methyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-(3-phenylpropyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-phenethylpiperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(5-(diethylamino)pentan-2-yl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- (R)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- (S)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(dimethylamino)-2,2-dimethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide;
- Chlorhydrate of 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid (2-diethylamino-ethyl)amide
or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof. - Preferably the invention concerns the following compounds:
- 9-chloro-N-(3-(2-methylpiperidin-1-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)phenyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-(4-methoxybenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-4-N,N-dimethylbenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-hydroxy-3-phenyl-2-pyrrolidin-1-ylmethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide
- Azepan-1-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- [1,4′]Bipiperidinyl-1′-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- N-(2-(azepan-1-yl)ethyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(2-(piperidin-1-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(4-((1-methylpiperidin-4-yl)methyl)piperazin-1-yl)methanone
- (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(4-(1-methylpiperidin-4-yl)piperazin-1-yl)methanone
- (9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(piperidin-1-yl)methanone
- N-((1-benzylpiperidin-4-yl)methyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-(3-phenylpropyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-((1-phenethylpiperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(5-(diethylamino)pentan-2-yl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 9-chloro-N-(3-(dimethylamino)-2,2-dimethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- Chlorhydrate of 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid (2-diethylamino-ethyl)amide
or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof. - As used hereabove or hereafter:
- “Alkyl” means an aliphatic hydrocarbon group which may be straight or branched having 1 to 20 carbon atoms in the chain. Preferred alkyl groups have 1 to 12 carbon atoms in the chain. “Branched” means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl.
- As used herein, the term “cycloalkyl” refers to an aromatic or non aromatic hydrocarbon mono, bi or multi cyclic ring of 3 to 10 carbon atoms formed by the removal of one hydrogen atom. A designation such as “C5-C7 cycloalkyl” refers to a cycloalkyl radical containing from 5 to 7 carbon atoms. Examples include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, etc. as well as the systems formed by their condensation or by the condensation with a phenyl group.
- “Alken” means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having 2 to 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to 12 carbon atoms in the chain; and more preferably about 2 to 4 carbon atoms in the chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, nonenyl, decenyl.
-
- “Halogen atom” refers to fluorine, chlorine, bromine or iodine atom; preferably fluorine and chlorine atom.
- “Perhalogenoalkyl” refers to an alkyl group as defined above where all H atoms are replaced by halogen atoms.
- “Polyhalogenoalkyl” refers to an alkyl group as defined above where one or more H atoms are replaced by halogen atoms.
- “Aryl” means an aromatic monocyclic or multicyclic hydrocarbon ring system of 6 to 14 carbon atoms, preferably of 6 to 10 carbon atoms. Exemplary aryl groups include phenyl or naphthyl.
- As used herein, the terms “heterocycle” or “heterocyclic” refer to a saturated, partially unsaturated or unsaturated, non aromatic stable 3 to 14, preferably 5 to 10-membered mono, bi or multicyclic rings wherein at least one member of the ring is a hetero atom. Typically, heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms. Preferable heteroatoms are oxygen, nitrogen and sulfur.
- Suitable heterocycles are also disclosed in The Handbook of Chemistry and Physics, 76th Edition, CRC Press, Inc., 1995-1996, p. 2-25 to 2-26, the disclosure of which is hereby incorporated by reference.
- Preferred non aromatic heterocyclic include, but are not limited to pyrrolidinyl, pyrazolidinyl, irriidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydro-pyranyl, dioxanyl, dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydrothiopyranyl, dithianyl, thiomorpholinyl, dihydro-pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydro-pyridyl, dihydropyridyl, tetrahydropyrimidinyl, dihydrothiopyranyl, azepanyl, as well as the fused systems resulting from the condensation with a phenyl group.
- As used herein, the term “heteroaryl” or aromatic heterocycles refers to a 5 to 14, preferably 5 to 10-membered aromatic hetero, mono-, bi- or multicyclic ring. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, as well as the fused systems resulting from the condensation with a phenyl group.
- “Alkyl”, “alkenyl”, “cycloalkyl”, “aryl”, “heteroaryl”, “heterocycle” and the likes refers also to the corresponding “alkylene”, “alkenylene”, “cycloalkylene”, “arylene”, “heteroarylene”, “heterocyclene” and the likes which are formed by the removal of two hydrogen atoms.
- As used herein, the term “patient” refers to either an animal, such as a valuable animal for breeding, company or preservation purposes, or preferably a human or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
- As used herein, a “therapeutically effective amount” refers to an amount of a compound of the present invention which is effective in preventing, reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions. The term “controlling” is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment.
- As used herein, the expression “pharmaceutically acceptable” refers to those compounds, materials, excipients, compositions or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problem complications commensurate with a reasonable benefit/risk ratio.
- As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, including mono, di or tri-salts thereof; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucoronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, lactic and the like. Further addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium.
- The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 20th ed., Mack Publishing Company, Easton, Pa., 2000, the disclosure of which is hereby incorporated by reference.
- The compounds of the general formula (I) having geometrical and stereoisomers are also a part of the invention.
- According to a further object, the present invention is also concerned with the process of preparation of the compounds of formula (I).
- The compounds and process of the present invention may be prepared in a number of ways well-known to those skilled in the art. The compounds can be synthesized, for example, by application or adaptation of the methods described below, or variations thereon as appreciated by the skilled artisan. The appropriate modifications and substitutions will be readily apparent and well known or readily obtainable from the scientific literature to those skilled in the art.
- In particular, such methods can be found in R. C. Larock, Comprehensive Organic Transformations, Wiley-VCH Publishers, 1999.
- It will be appreciated that the compounds of the present invention may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms. Thus, all chiral, diastereomeric, racemic forms, isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well-known in the art how to prepare and isolate such optically active forms. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
- Additionally, the process of the invention may lead to several regioisomers which are all encompassed by the present invention. Regioisomers are generally isolated by chromatography.
- Compounds of the present invention may be prepared by a variety of synthetic routes. The reagents and starting materials are commercially available, or readily synthesized by well-known techniques by one of ordinary skill in the arts. All substituents, unless otherwise indicated, are as previously defined.
- In the reactions described hereinafter, it may be necessary to protect reactive functional groups, for example hydroxyl, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T. W. Greene and P. G. M. Wuts in Protective Groups in Organic Chemistry, 3rd ed., John Wiley and Sons, 1999; J. F. W. McOmie in Protective Groups in Organic Chemistry, Plenum Press, 1973.
- Some reactions may be carried out in the presence of a base. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used in reactions of this type may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: sodium hydroxide, potassium carbonate, triethylamine, alkali metal hydrides, such as sodium hydride and potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali metal alkoxides, such as sodium methoxide and sodium ethoxide.
- Usually, reactions are carried out in a suitable solvent. A variety of solvents may be used, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, such as dimethylformamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran.
- The reactions can take place over a wide range of temperatures. In general, it is found convenient to carry out the reaction at a temperature of from 0° C. to 150° C. (more preferably from about room temperature to 100° C.). The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 20 hours will usually suffice.
- The compound thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary, after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well-known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography.
- The process of preparation of a compound of formula (I) of the invention is a further object of the present invention.
- According to a first aspect, a compound of the invention of formula (I) can be obtained by reacting a corresponding compound of formula (VII):
- by peptidic coupling
with a corresponding compound of formula (VIII): - where i, j, k, n, Z, Ri, Rj and Rk are defined as in formula (I), R is OH or a halogen and X′ and Y′ are identical to X and Y respectively, or a precursor thereof, or an amino protecting group, optionally followed by alkylation(s) or deprotection as the case may be, respectively.
- Said compound of formula (VII) may be obtained by a corresponding compound of
- where i, j, n, Z, Ri, Rj are defined as in formula (I), by functionalization, i.e. the Rk group is introduced via convenient functionalization of the keto group which include halogenations, reduction then dehydration, nucleophilic addition followed by dehydration. In particular to introduce Rk=Hal, this functionalization comprises the steps of halogenations, reduction then deshydratation.
- The present invention also concerns compound of formula (VI):
- where i, j, n, Z, Ri, Rj are defined as in formula (I),
with the exception of: - According to a particular embodiment, compounds of formula (VI) are the following
- The compound of formula (VI) may be obtained by coupling compounds (II) and (III) or (IV) and (V) according to either of the two pathways below.
- First, a condensation between ketones (II) or substituted ketones (IV) is performed with a substituted aniline (III) or (V) leading to the tricyclic acids (VI). Amino terephthalic acids (III) or (V) and the corresponding ketones (II) (pathway I) or (IV) (pathway II) are mixed and stirred in the appropriate solvent. Depending on the reactivity, mixture can be heated or catalysed by the use of acidic conditions. In the case of pathway (II), the reaction is performed via the cyclisation of an intermediate enamine of (IV) and (V).
- Further, functionalization of (VI) affords compounds (VII) as acyl halides or carboxylic acids. Peptidic coupling is performed using standard conditions depending on the nature of (VII). Amines HNXY can be either be commercially available or prepared using classical methods prior to coupling to compounds (VII).
- An alternative approach was used in the case where —NXY is a diamine. It include the coupling of compounds (VII) with mono-protected—secondary or primary—amines precursor followed by deprotection and one or two successive alkylations using electrophilic reagents such as halides derivatives or aldehydes.
- The term “precursor” is used herein to refer to compounds which differ from the indicated or desired compounds by the presence and/or absence of groups or functions. Such groups or functions may be introduced, transformed and/or omitted by common functionalization reactions, known from the skilled person.
- The functionalization reaction may be carried out by application or adaptation of known methods.
- The above reactions can be carried out by the skilled person by applying or adapting the methods illustrated in the examples hereinafter.
- Further, the process of the invention may also comprise the additional step of isolating the compound of formula (I). This can be done by the skilled person by any of the known conventional means, such as the recovery methods described above.
- Generally, the starting products (II), (III), (IIV), (V) and (VIII) are commercially available mainly from Aldrich or Acros or other typical chemicals supplier or may be obtained by applying or adapting any known methods or those described in the examples.
- According to a further object, the present invention concerns also the pharmaceutical compositions comprising a compound of formula (I) as defined above or a tautomer thereof and/or its pharmaceutically acceptable salts, with a pharmaceutically acceptable excipient.
- Preferred embodiments of formula (I) are as defined above in respect of the compounds of the invention.
- According to a still further object, the present invention concerns a compound of formula (I) of the invention for inhibiting cysteine protease.
- The compounds of the invention are useful for inhibiting cysteine proteases, in particular specific de-ubiquitination enzymes such as USPs, and more particularly USP-7 in patients in the need thereof.
- The compounds of the invention are particularly useful for treating and/or preventing cancer and metastasis, more particularly prostate and/or colon cancers, neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, immunological disorders, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, viral infections and diseases, and/or viral infectivity and/or latency, bacterial infections and diseases.
- In particular, said viral infections and diseases are chosen from herpes simplex-1 or -2 viral infections, hepatitis A, hepatitis C, SARS coronavirus infection and disease, Epstein-Barr virus, rhinoviral infections and diseases, adenoviral infections and diseases, poliomyelitis.
- According to an aspect, said compounds inhibit one or more viral cysteine proteases.
- Bacterial cysteine proteases may be chosen from streptopain, clostripain, staphylococcal cysteine protease, gingipain.
- The present invention also concerns the combinations comprising a compound of formula (I) as defined in anyone of claims 1 to 8 or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof,
- with one or more active agents chosen from anti-cancer agents, neurological agents, thrombolytic agents, antioxidant agents. anti-infective, anti-hypertensive agents, diuretic agents, thrombolytic agents, immunosuppressive agents, cardiovascular agents, immunomodulatory agents, anti-inflammatory agents, antiviral agents, anti-bacterial agents.
- The present invention also concerns the corresponding methods of treatment comprising the administration of a compound of the invention together with a pharmaceutically acceptable carrier or excipient to a patient in the need thereof.
- The identification of those subjects who are in need of treatment of herein-described diseases and conditions is well within the ability and knowledge of one skilled in the art. A veterinarian or a physician skilled in the art can readily identify, by the use of clinical tests, physical examination, medical/family history or biological and diagnostic tests, those subjects who are in need of such treatment.
- A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
- The amount of a compound of formula (I), which is required to achieve the desired biological effect, will vary depending upon a number of factors, including the chemical characteristics (e.g. hydrophobicity) of the compounds employed, the potency of the compounds, the type of disease, the species to which the patient belongs, the diseased state of the patient, the route of administration, the bioavailability of the compound by the chosen route, all factors which dictate the required dose amounts, delivery and regimen to be administered.
- “Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
- As used herein, “pharmaceutically acceptable excipient” includes any carriers, diluents, adjuvants, or vehicles, such as preserving or antioxidant agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well-known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions as suitable therapeutic combinations.
- In the context of the invention, the term “treating” or “treatment”, as used herein, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
- “Therapeutically effective amount” means an amount of a compound/medicament according to the present invention effective in preventing or treating a pathological condition requiring the inhibition of an active cysteine protease involved in its pathogenesis.
- According to the invention, the terms “patient” or “patient in need thereof”, are intended for an animal or a human being affected or likely to be affected with a pathological condition involving an active cysteine protease in its pathogenesis. Preferably, the patient is human.
- In general terms, the compounds of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v compound for parenteral administration. Typical dose ranges are from 1 μg/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 100 mg/kg of body weight per day or an equivalent dose in a human child. The preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the route of administration (intravenous, intramuscular, or other), the pharmacokinetic properties of the compound by the chosen delivery route, and the speed (bolus or continuous infusion) and schedule of administrations (number of repetitions in a given period of time).
- The compounds of the present invention are also capable of being administered in unit dose forms, wherein the expression “unit dose” means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter. As such, typical total daily dose ranges are from 0.01 to 100 mg/kg of body weight. By way of general guidance, unit doses for humans range from 1 mg to 3000 mg per day. Preferably, the unit dose range is from 1 to 500 mg administered one to six times a day, and even more preferably from 10 mg to 500 mg, once a day. Compounds provided herein can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients. Such unit dose compositions may be prepared for use by oral administration, particularly in the form of tablets, simple capsules or soft gel capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, for example, topically in ointments, creams, lotions, gels or sprays, or via trans-dermal patches.
- The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2000.
- Preferred formulations include pharmaceutical compositions in which a compound of the present invention is formulated for oral or parenteral administration.
- For oral administration, tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate. Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule. In addition, dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents. Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings. In addition, the active compounds may be incorporated into fast dissolve, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal. Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination.
- Liquid preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like. Non-aqueous solvents include alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl oleate. Aqueous carriers include mixtures of alcohols and water, buffered media, and saline. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds. Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
- Alternative modes of administration include formulations for inhalation, which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate. Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate. Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations. Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
- The invention is further illustrated but not restricted by the description in the following examples and figures as a non limiting illustration for selective inhibition of USP7 deubiquitinating activity over a panel of active DUBs in physiological conditions.
- Representative compounds of the invention can be synthesized according to the following procedures.
- NMR spectra were recorded at 300 or 400 MHz for 1H and at 75 or 100, MHz for 13C on a Bruker or Varian spectrometer with CDCl3 or DMSO-d6 as solvent. The chemical shifts are given in ppm, referenced to the internal TMS or deuterated solvent signal.
- LC-MS analysis was used to analyze and purify target compounds. LC-MS analyses were performed using an Waters Micromass, Bruker Esquire 3000 (ESI-IT) or Agilent Iontrap XCT-Plus mass spectrometers and Waters Alliance 2790 or Agilent 1100 Series LC systems with UV and/or DAD detection. Columns: Waters XTerra MS C18, 30×2.1 mm (3.5 μm), Atlantis T3 C18, 3 μm, 50 mm×2.1 mm or Inertsil C8, 250 mm, 4.6 mm, 5 μm. Flow rates: 0.8-1.2 ml/min, Gradients: a) water 10% MeOH, ammonium formate 10 mM, to 100% MeOH or b) 95% Water-acetonitrile, 0.1% HCOOH to 95% acetonitrile.). UV detection: 190 to 400 nm. All compounds were >95% pure.
-
- To a suspension of 2-amino terephthalic acid (12 g, 6.6 mmols) in diphenyl ether (120 mL), cyclohexanone (25 mL) was added and the reaction mixture was heated to 250° C. for 10 min. Reaction completion was monitored by LC/MS (75% starting material and 25% Product formation was observed). Cyclohexanone (25 mL) was added and the reaction mixture was heated to 250° C. for another 10 min. (LC/MS showed 50% product formation). The above process was repeated till LC/MS showed complete product formation (Starting material <2%). The reaction mixture was cooled to 25° C., product was filtered, washed with hexane (100 mL) and dried under vacuum to get 15.8 g of (Via) (98%) as a yellow solid.
- 1H NMR (300 MHz, DMSO) δ 13.27 (s, 1H), 11.54 (s, 1H), 8.14-8.11 (d, 2H, J=8.4 Hz), 7.72-7.70 (m, 1H), 2.72 (m, 2H), 2.44 (m, 2H), 1.76-1.72 (m, 4H).
- MS: calcd for C14H13NO3, 243.09. found 243.8 (M+H)+.
- A suspension of 9-oxo-5,6,7,8, 9,10-hexahydro-acridine-3-carboxylic acid (Via) (10 g, 4.1 mmols) in phosphorous oxychloride (50 mL) was heated to 100° C. for 1 h. Reaction completion was monitored by TLC. After completion, the reaction mixture was cooled to 25° C. and excess phosphorous oxychloride was removed under vacuum. The residue was mixed with ice (50 g) and the pH was adjusted to 4-5 with solid sodium bicarbonate. The solid obtained was filtered, washed with water (250 mL) and dried under vacuum to get 9.6 g (88%) of compound (VIIa) as a white solid.
- 1H NMR (300 MHz, DMSO) δ 13.37 (s, 1H), 8.44 (s, 1H), 8.19-8.16 (d, 1H, J=8.7 Hz), 8.09-8.07 (dd, 1H, J=8.7 Hz, 1.5 Hz), 3.06 (m, 2H), 2.96 (m, 2H), 1.99-1.89 (m, 4H).
- MS: calcd for C14H12ClNO2, 261.06. found 261.8 (M+H)+.
- To a 0.1M DMF solution of the heterocyclic acids VII, triethylamine was added (2 equiv.) followed by the corresponding amines (1 equiv.) and coupling agent (TBTU, HATU, OHBT, 1 equiv.). The corresponding mixtures were stirred for 1-12 h at 20° C. Concentrated HCl was added and after 5 min stirring, the mixtures were under vacuum. The crude compounds were extracted with 20 mL d'AcOEt, washed with 10 mL of aqueous 0.5M NaHCO3 solution and 10 mL of water. The organics phase were dried over MgSO4 then evaporated under vacuum. Purification using silicagel (gradient CH2Cl2 CH2Cl2/MeOH 9/1) or preparative LC/MS affords the pure corresponding amides.
- Selected data of some of the compounds that were prepared by application or adaptation of the method disclosed above are shown below:
- 1H NMR (400 MHz, DMSO-d6) δ 8.77 (t, J=5.7 Hz, 1H), 8.47 (d, J=1.8 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.04 (dd, J=1.7, 8.7 Hz, 1H), 7.36 (s, 1H), 7.18 (t, J=7.5 Hz, 1H), 7.09 (s, 1H), 7.07 (d, J=7.7 Hz, 1H), 7.04 (d, J=7.5 Hz, 1H), 3.38 (s, 2H), 3.32-3.29 (m, 2H), 3.21 (d, J=6.7 Hz, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.79 (m, 2H), 2.28 (s, 3H), 1.94-1.84 (m, 6H), 1.69 (s, 1H), 1.66 (s, 1H), 1.63-1.53 (m, 1H), 1.28-1.14 (m, 2H).
- MS: calcd for C28H32ClN3O, 461.22. found 462.17 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.72 (t, J=5.6 Hz, 1H), 8.43 (d, J=1.7 Hz, 1H), 8.16 (d, J=8.6 Hz, 1H), 8.02 (dd, J=1.7, 8.8 Hz, 1H), 7.29 (m, 4H), 7.18 (m, 1H), 3.54 (s, 2H), 3.32 (m, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.46 (m, 4H), 1.89 (m, J=3.73 Hz, 4H), 1.74 (m, J=7.2 Hz, 2H), 0.97 (t, J=7.1 Hz, 3H).
- MS: calcd for C26H30ClN3O, 435.21. found 436.17 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.75 (t, J=5.4 Hz, 1H), 8.45 (d, J=1.8 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.04 (dd, J=1.8, 8.7 Hz, 1H), 3.37-3.28 (m, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.44 (t, J=7.1 Hz, 2H), 2.32 (t, J=7.1 Hz, 4H), 1.9 (m, J=3.7 Hz, 4H), 1.68 (m, J=7.0 Hz, 2H), 1.39 (m, J=7.3 Hz, 4H), 0.83 (t, J=7.3 Hz, 6H).
- MS: calcd for C23H32ClN3O, 401.22. found 402.22 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6): δ (ppm): 8.69 (t, J=5.7 Hz, 1H), 8.44 (d, J=1.8 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 8.04 (dd, J=1.8, 8.7 Hz, 1H), 3.41-3.28 (m, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.59 (dd, J=6.8, 8.2 Hz, 2H), 2.52 (q, J=7.1 Hz, 2H), 1.9 (m, J=3.7 Hz, 4H), 0.98 (t, J=7.1 Hz, 6H)
- MS: calcd for C21H26ClN3O, 359.18. found 360.19 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.86 (t, J=5.5 Hz, 1H), 8.44 (d, J=1.8 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.04 (dd, J=1.8, 8.7 Hz, 1H), 3.40-3.28 (m, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.50-2.40 (m, 6H), 1.9 (m, J=3.7 Hz, 4H), 1.78-1.64 (m, 6H).
- MS: calcd for C21H26ClN3O, 371.18. found 372.17 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.8 (t, J=5.5 Hz, 1H), 8.44 (d, J=1.8 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.03 (dd, J=1.7, 8.7 Hz, 1H), 3.38-3.26 (m, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.46 (q, J=7.2 Hz, 5H), 1.90 (m, 4H), 1.68 (m, J=7.0 Hz, 2H), 0.95 (t, J=7.1 Hz, 6H).
- MS: calcd for C21H28ClN3O, 373.93. found 374.19 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.17 (d, J=8.6 Hz, 1H), 7.85 (d, J=1.7 Hz, 1H), 7.6 (dd, J=1.7, 8.6 Hz, 1H), 3.61 (dd, J=5.6, 6.6 Hz, 2H), 3.35-3.28 (m, 2H), 3.05 (m, 2H), 2.98 (m, 2H), 1.89 (m, 4H), 1.76 (m, J=6.2 Hz, 2H), 1.60 (m, 2H), 1.53 (m, 4H).
- MS: calcd for C22H23ClN2O, 342.15. found 343.17 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.84 (t, J=5.5 Hz, 1H), 8.45 (d, J=1.8 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.04 (dd, J=1.8, 8.7 Hz, 1H), 3.38-3.28 (m, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.36 (m, J=7.0 Hz, 9H), 2.19 (t, J=7.7 Hz, 2H), 1.9 (m, J=4.0 Hz, 4H), 1.71 (m, J=7.0 Hz, 2H), 1.4 (m, J=7.41 Hz, 2H), 0.83 (t, J=7.4 Hz, 3H).
- MS: calcd for C24H33ClN40, 428.23. found 429.20 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.76 (t, J=5.6 Hz, 1H), 8.44 (d, J=1.8 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.02 (dd, J=1.7, 8.8 Hz, 1H), 7.33-7.16 (m, 5H), 3.47 (s, 2H), 3.38 (d, J=6.7 Hz, 1H), 3.34 (d, J=6.8 Hz, 1H), 3.33-3.28 (m, 2H), 3.06 (m, 2H), 2.99 (m, 2H), 2.42 (t, J=6.9 Hz, 1H), 2.12 (s, 3H), 1.90 (m, J=3.1 Hz, 1H), 1.77 (m, J=7.0 Hz, 2H).
- MS: calcd for C25H26ClN3O, 421.19. found 422.14 (M+H)+.
- 1H NMR (400 MHz, DMSO-d6) δ 8.82 (t, J=5.5 Hz, 1H), 8.45 (d, J=1.8 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.04 (dd, J=1.7, 8.7 Hz, 1H), 3.38-3.28 (m, 2H), 3.06 (m, 2H), 2.98 (m, 2H), 2.36 (m, J=7.0 Hz, 8.5H), 2.14 (s, 3H), 1.9 (m, J=4.1 Hz, 4H), 1.71 (m, J=7.0 Hz, 2H).
- MS: calcd for C22H29ClN4O, 400.20. found 401.20 (M+H)+.
- 1H NMR (DMSO-d6, 400 MHz) δ (ppm) 1.50 (m, 2H), 1.62 (m, 2H), 1.90 (m, 4H), 1.95 (m, 2H), 2.05 (m, 2H), 2.22 (s, 3H), 2.95 (m, 3H), 3.03 (m, 2H), 3.34 (m, 2H), 8.00 (dd, J=8.8 Hz, J=1.7 Hz, 1H), 8.13 (d, J=8.8 Hz, 1H), 8.43 (d, J=1.5 Hz, 1H), 8.79 (t, J=5.5 Hz, 1H).
- MS: calcd for C21H26ClN3O, 371.18. found 371.95 (M+H)+.
- 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 1.71 (m, 4H), 1.85 (m, 4H), 2.50 (m, 2H), 2.97 (m, 2H), 3.05 (m, 2H), 3.37 (m, 2H), 3.66 (m, 2H), 4.54 (d, J=5.7 Hz, 2H), 7.28 (m, 4H), 8.09 (dd, J=8.8 Hz, J=1.6 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 8.52 (d, J=1.4 Hz, 1H), 9.36 (t, J=6.0 Hz, 1H).
- MS: calcd for C26H28ClN3O, 433.19. found 433.93 (M+H)+.
- 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 1.71 (m, 4H), 1.91 (m, 4H), 2.54 (m, 2H), 3.00 (m, 2H), 3.09 (m, 2H), 3.35 (m, 2H), 3.61 (s, 2H), 7.07 (d, J=7.5 Hz, 1H), 7.31 (d, J=7.5 Hz, 1H), 7.75 (d, J=8.6 Hz, 1H), 7.84 (s, 1H), 8.15 (dd, J=9.0 Hz, J=1.6 Hz, 1H), 8.23 (d, J=8.6 Hz, 1H), 8.65 (d, J=1.6 Hz, 1H).
- MS: calcd for C25H26ClN3O, 419.18. found 419.94 (M+H)+.
- RMN 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.99 (d, J=6.3 Hz, 3H), 1.21 (m, 2H), 1.40 (m, 1H), 1.57 (m, 3H), 1.70 (m, 2H), 1.90 (m, 4H), 2.08 (m, 1H), 2.28 (m, 2H), 2.72 (m, 1H), 2.82 (m, 1H), 2.95 (m, 2H), 3.05 (m, 2H), 3.30 (m, 2H), 8.03 (dd, J=3.7 Hz, J=1.7 Hz, 1H), 8.15 (d, J=8.8 Hz, 1H), 8.44 (d, J=1.4 Hz, 1H), 8.80 (t, J=5.4 Hz, 1H).
- MS: calcd for C22H30ClN3O, 399.21. found 400.00 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.60 (m, 4H), 1.75 (m, 4H), 1.90 (m, 4H), 2.97 (m, 2H), 3.06 (m, 2H), 3.14 (m, 6H), 3.75 (m, 2H), 8.06 (dd, J=8.8 Hz, J=1.7 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 8.49 (d, J=1.5 Hz, 1H), 8.95 (m, 1H).
- MS: calcd for C22H28ClN3O, 385.19. found 385.96 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm) 1.37 (m, 2H), 1.48 (m, 4H), 1.88 (m, 4H), 2.39 (m, 4H), 2.49 (m, 2H), 2.95 (m, 2H), 3.04 (m, 2H), 3.43 (m, 2H), 8.03 (dd, J=8.8 Hz, J=1.5 Hz, 1H), 8.14 (d, J=8.8 Hz, 1H), 8.43 (s, 1H), 8.69 (t, J=5.3 Hz, 1H).
- MS: calcd for C21H26ClN3O, 371.18. found 371.95 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.08 (m, 2H), 1.42 (s, 1H), 1.63 (m, 2H), 1.78 (m, 2H) 1.88 (m, 4H), 2.10 (s, 3H), 2.12 (m, 2H), 2.35 (m, 4H), 2.71 (m, 2H), 2.95 (m, 2H), 3.03 (m, 2H), 3.37 (m, 2H), 3.53 (m, 2H), 7.61 (dd. J=8.6 Hz, J=1.5 Hz, 1H), 7.87 (d, J=1.4 Hz, 1H), 8.16 (d, 8.6 Hz, 1H).
- MS: calcd for C28H33ClN4O, 440.23. found 441.02 (M+H)+.
- 1H RMN (IDMSO-d6, 400 MHz) δ (ppm): 1.40 (m, 2H), 1.68 (m, 2H), 1.83 (m, 2H), 1.88 (m, 4H), 2.11 (s, 3H), 2.16 (m, 1H), 2.51 (m, 2H), 2.55 (m, 2H), 2.76 (m, 2H), 2.96 (m, 2H), 3.04 (m, 2H), 3.35 (m, 2H), 3.65 (m, 2H), 7.62 (dd, J=8.3 Hz, J=1.2 Hz, 1H), 7.88 (s, 1H), 8.17 (d, J=8.7 Hz, 1H).
- MS: calcd for C24H31ClN4O, 426.22. found 427.01 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.63 (m, 6H), 1.89 (m, 4H), 2.98 (m, 2H), 3.05 (m, 2H), 3.34 (m, 2H), 3.59 (m, 2H), 7.61 (dd, J=8.6 Hz, J=1.6 Hz, 1H), 7.87 (d, J=1.3 Hz, 1H), 8.18 (d, J=8.6 Hz, 1H).
- MS: calcd for C19H21ClN2O, 328.13. found 328.97 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.21 (m, 2H), 1.61 (m, 1H), 1.68 (m, 2H), 1.90 (m, 6H), 2.80 (m, 2H), 2.98 (m, 2H), 3.05 (m, 2H), 3.19 (m, 2H), 3.52 (s, 2H), 7.24 (m, 1H), 7.31 (m, 4H), 8.04 (dd, J=8.6 Hz, J=1.4 Hz, 1H), 8.17 (d, J=8.6 Hz, 1H), 8.46 (d, J=1.4 Hz, 1H), 8.78 (t, J=5.4 Hz, 1H).
- MS: calcd for C27H30ClN3O, 447.21. found 447.98 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.21 (m, 3H), 1.50 (m, 1H), 1.70 (m, 4H), 1.90 (m, 6H), 2.27 (m, 1H), 2.55 (m, 2H), 2.89 (m, 2H), 2.98 (m, 2H), 3.06 (m, 2H), 3.21 (m, 2H), 7.17 (m, 3H), 7.27 (m, 2H), 8.04 (dd, J=8.6 Hz, J=1.6 Hz, 1H), 8.16 (d, J=8.6 Hz, 1H), 8.47 (d, J=1.4 Hz, 1H), 8.77 (t, J=5.7 Hz, 1H).
- MS: calcd for C29H34ClN3O, 475.24. found 476.01 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.18 (m, 2H), 1.60 (m, 1H), 1.72 (m, 2H), 1.93 (m, 6H), 2.53 (m, 2H) 2.73 (m, 2H), 2.97 (m, 4H), 3.06 (m, 2H), 3.22 (m, 2H), 7.20 (m, 5H); 8.05 (d, J=8.3 Hz, 1H), 8.17 (d, J=8.3 Hz, 1H), 8.48 (s, 1H), 8.78 (t, J=5.5 Hz, 1H).
- MS: calcd for C28H32ClN3O, 461.22. found 462.01 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 0.97 (t, J=7.1 Hz, 6H), 1.20 (m, 4H), 1.52 (m, 5H), 1.90 (m, 4H), 2.53 (m, 4H), 2.98 (m, 2H), 3.04 (m, 2H), 4.10 (m, 1H), 8.05 (dd, J=8.4 Hz, J=1.4 Hz, 1H), 8.16 (d, J=8.8 Hz, 1H), 8.48 (d, J=1.3 Hz, 1H), 8.50 (d, J=8.1 Hz, 1H).
- MS: calcd for C23H32ClN3O, 401.22. found 401.96 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.11 (t, J=7.1 Hz, 3H), 1.74 (m, 3H), 1.90 (m, 4H) 2.83 (m, 1H), 2.50 (m, 1H), 2.85 (m, 1H), 2.99 (m, 3H), 3.07 (m, 2H), 3.18 (m, 1H) 3.25 (m, 1H), 3.55 (m, 2H), 8.06 (dd, J=8.7 Hz, J=1.7 Hz, 1H), 8.18 (d, J=8.7 Hz, 1H), 8.48 (d, J=1.5 Hz, 1H), 8.80 (t, J=5.2 Hz, 1H).
- MS: calcd for C21H26ClN3O, 371.18. found 371.92 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.11 (t, J=7.1 Hz, 3H), 1.74 (m, 3H), 1.90 (m, 4H) 2.83 (m, 1H), 2.50 (m, 1H), 2.85 (m, 1H), 2.99 (m, 3H), 3.07 (m, 2H), 3.18 (m, 1H), 3.25 (m, 1H), 3.55 (m, 2H), 8.06 (dd, J=8.8 Hz, J=1.8 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 8.48 (d, J=1.5 Hz, 1H), 8.80 (m, 1H).
- MS: calcd for C21H26ClN3O, 371.18. found 371.92 (M+H)+.
- 1H RMN (DMSO-d6, 400 MHz) S (ppm): 0.94 (s, 6H), 1.89 (m, 4H), 2.29 (m, 2H), 2.34 (s, 6H), 2.96 (m, 2H), 3.05 (m, 2H), 3.26 (d, J=5.9 Hz, 2H), 8.01 (dd, J=8.7 Hz, J=1.8 Hz, 1H), 8.16 (d, J=8.7 Hz, 1H), 8.43 (d, J=1.5 Hz, 1H), 8.77 (t, J=5.9 Hz, 1H).
- MS: calcd for C21H28ClN3O, 373.19. found 373.92 (M+H)+.
- 9-chloro-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 1H RMN (DMSO-d6, 400 MHz) δ (ppm): 1.84 (m, 6H), 2.55 (m, 2H), 2.67 (m, 2H), 2.80 (m, 2H), 2.96 (m, 2H), 3.05 (m, 2H), 3.39 (m, 2H), 3.57 (s, 2H), 7.09 (m, 4H), 7.99 (dd, J=8.8 Hz, J=1.7 Hz, 1H), 8.09 (d, J=8.8 Hz, 1H), 8.44 (d, J=1.5 Hz, 1H), 8.86 (t, J=5.4 Hz, 1H).
- MS: calcd for C26H28ClN3O, 433.19. found 433.94 (M+H)+.
- The following compounds were also synthesized by using the method mentioned above:
-
- MS: calcd for C26H28ClN3O, 433.19. found 433.91 (M+H)+.
-
- MS: calcd for C28H32ClN3O2, 477.22. found 477.99 (M+H)+.
-
- MS: calcd for C29H35ClN4O, 490.25. found 491.00 (M+H)+.
-
- MS: calcd for C20H24ClN3O, 357.16. found 357.93 (M+H)+.
-
- MS: calcd for C28H32ClN3O2, 477.22. found 477.99 (M+H)+.
-
- MS: calcd for C22H26ClN2O. 2HCl, 359.18. found 360.01 (M+H)+.
- Other intermediates compounds of formula (VII) were synthesized to give the compounds of formula (I) by a peptic coupling:
-
- To a suspension of amino acid in diphenyl ether (3 mL), cyclohexanone was added and the reaction mixture was heated to 250° C. for 10 min. Reaction completion was monitored by LC/MS which showed the desired product, the intermediate hydrate but still starting material. Cyclohexanone (0.63 mL) was added and the reaction mixture was heated to 250° C. for another 10 min (monitored by LC/MS, still starting material). The above process was repeated till LC/MS showed complete product formation (5× overall). Excess of cyclohexanone led to lower boiling point of the reaction mixture because cyclohexanone boiling point=155° C. At the end, excess of cyclohexanone was removed under vacuum (rota) and the residue was heated at 250° C. for another 10 min (this permits to reach higher temperature In the reaction mixture, mixture temperature was controlled), LCMS showed the desired product, the reaction mixture was cooled to 25° C.; product was filtered, washed with pentane and dried under vacuum to get 549 mg as a brown solid (Mass excess could be diphenyl ether as 1HNMR showed too much aromatic protons). The crude product was used without further purification.
- 1H NMR (DMSO-d6, 300 MHz) δ=1.90-2.00 (m, 4H), 2.98-3.07 (m, 2H), 3.13-3.22 (m, 2H), 7.87 (dd, 1H, J=7.5 Hz and J=9.0 Hz), 8.47 (dd, 1H, J=1.5 Hz and J=9.0 Hz), 8.57 (dd, 1H, J=1.5 Hz and J=7.5 Hz)
- 13C NMR (DMSO-d6, 75 MHz) δ=21.2 and 21.4 (2C), 26.8 (1C), 32.8 (10), 123.5 and 124.7 (2C), 127.4-134.1 (4C), 142.7 and 142.9 (2C), 159.8 (1C), 165.9 (1C)
- A suspension of crude carboxylic acid in POCl3 was heated for 1 h at 100° C. The reaction was followed with LCMS which showed no more starting material but the desired product. POCl3 excess was removed under vacuum and the residue was poured in ice, the aqueous residue obtained was triturated, pH was adjusted to 4 with solid NaHCO3, and the solid obtained was filtered to give 127 mg of product alter drying under vacuum. The desired product was purified by reverse flash column chromatography (using Biotage flash+, MeCN/H20 40/60). 90 mg of the pure desired product was obtained as a beige solid (28%).
- 1H NMR (DMSO-d6, 300 MHz) δ=1.90-2.00 (m, 4H), 2.98-3.07 (m, 2H), 3.13-3.22 (m, 2H), 7.87 (dd, 1H, J=7.5 Hz and J=9.0 Hz), 8.47 (dd, 1H, J=1.5 Hz and J=9.0 Hz), 8.57 (dd, 1H, J=1.5 Hz and J=7.5 Hz)
- 13C NMR (DMSO-d6. 75 MHz) δ=21.2 and 21.4 (2C), 26.8 (1C), 32.8 (1C), 123.5 and 124.7 (2C), 127.4-134.1 (4C), 142.7 and 142.9 (2C), 159.8 (1C), 165.9 (1C)
-
- Potassium permanganate was dissolved in water (400 mL) in a flask fitted with a thermometer and a reflux condenser. 4-Nitro-m-xylene was added. The mixture was cautiously heated to 85° C.
- Cooling to maintain the reaction mixture at 85° C. was necessary (the hot bath was removed and put back). After 20 min, the mixture was gently refluxed for 3 h (the purple colour had disappeared and the mixture was almost black). The warm mixture was filtered through celite. The cold filtrate was acidified with concentrated sulphuric acid and a milky suspension was obtained. Extraction with EtOAc (3×0.5 L). The combined organic layers were dried (Na2SO4) and concentrated to give a white solid; purification by flash chromatography using EtOAc/heptane/AcOH 10:10:1 as eluent gave 2 fractions of white solid (42% global yield).
- A solution of nitro-isophtalic acid in EtOH (absolu, 40 mL) was injected in ihe H-cube (50° C., Pd/C 10%, Full H2, 1 mL/min).
- The resulting solution was controlled with LCMS which showed full conversion toward the desired product.
- In order to avoid nitroso side product traces, the resulting was injected a second time in the H-Cube using the method described above. EtOH was removed under vacuum and 0.83 g al the pure desired aniline was obtained as a white solid (97% yield). The clean aniline was used without further purification in condensation step.
- To a suspension of 2-amino isophtalic acid in diphenyl ether (8 mL) was added
- cyclohexanone (1.5 mL) and the reaction mixture was heated to 250° C. for 10 min. Reaction completion was monitored by LCMS. Cyclohexanone was added and the reaction mixture was heated to 250° C. for another 10 min. The above process was repeated till LCMS showed complete product formation. But after 6 cycles LCMS showed no more progression so cyclohexanone was completely removed under vacuum. Excess of cyclohexanone led to lower boiling point of the reaction mixture because cyclohexanone boiling point=155° C. Excess of cyclohexanone was removed under vacuum (rota), then, 1.5 mL of cyclohexanone was added to the residue and the reaction mixture was heated to 250° C. for 10 min (this permits to reach higher temperature in the reaction mixture). LCMS showed complete conversion toward the desired product.
- The reaction mixture was cooled to 25° C., product was filtered, washed with pentane and then with MeOH, dried under vacuum to get the pure desired product as a beige solid (700 mg, 63%).
- A suspension of crude carboxylic acid in POCl3 was heated for 1 h at 100° C. The reaction was followed with LCMS which showed complete conversion toward the desired product. The reaction was cooled to rt and POCl3 excess was removed under vacuum. The residue was poured in ice and pH was adjusted to 4 with solid NaHCO3. The aqueous mixture was triturated and let overnight at 5° C. (fridge). The solid obtained was filtered and washed with water to get a dark grey powder. Rapid flash chromatography (AcOEt/
MeOH 95/5) afforded 76 mg of the pure desired product (beige solid, 44% yield). 1H NMR showed traces or EtOAc, so the product was dried overnight under high vacuum and ½ h at 120° C. at ambient pressure. - 1H NMR (DMSO-d6. 300 MHz) δ=1.85-1.95 (m, 4H), 2.93-3.02 (m, 2H), 3.03-3.10 (m, 2H), 8.01 (d, 1H, J=9.0 Hz), 8.20 (dd, 1H, J=2.0 Hz and J=9.0 Hz), 8.75 (d, 1H, J=2.0 Hz), 13.35 (br s, 1H)
- 13C NMR (DMSO-d6, 75. MHz) δ=22.2 (2C), 27.4 (1C), 34.1 (1C), 124.2 (1C), 126.1 (1C), 129.2-130.2 (4C), 141.4 (1C), 148.1 (1C), 162.5 (1C), 167.1 (1C)
-
- To a suspension al 2-Amincterephthalic acid (1 g, 0.005 mols) in diphenyl ether (15 mL) added cycloheptanone (40 mL) at 25° C. and the reaction mixture was heated to 250° C. for 15 min. LC/MS showed 95% product formation. The reaction mixture was cooled to 23-25° C. and added hexane (20 Vol) and stirred for 20 min. The precipitated solid was filtered, washed with hexane (20 Vol) and dried under vacuum. The crude product (1.39 g) was taken as such for next step.
- 1H NMR (300 MHz, DMSO): δ=13.28 (bs, 1H), 11.61 (bs, 1H), 8.14-8.16 (d, 2H, J=8.1 Hz), 7.73-7.757 (m, 1H), 2.77-2.84 (m, 4H), 1.69-1.81 (m, 4H), 1.46 (m, 2H).
- Compound VIf (200 mg, 0.0007 mols) was taken in phosphorus oxychloride (10 Vol) and refluxed at 95° C. for 8 hrs. Reaction was monitored by TLC. After completion, the reaction mixture was cooled to 25° C. and quenched the reaction mass with crushed ice and basified to a pH 4 to 5 using 10% NaHCO3 solution. The aqueous layer was extracted with ethyl acetate (10 Vol×3). Combined organic layer was dried over sodium sulphate and concentrated to get yellow solid (180 mg, 86%).
- 1H NMR (300 MHz, DMSO): δ=8.456-8.460 (d, 1H, J=1.2 Hz), 8.18-8.21 (d, 1H, J=8.7 Hz), 8.104-8.138 (d, 1H. 8.7 Hz), 3.20-3.25 (m, 4H), 1.85-1.86 (m, 2H), 1.70-1.73 (m, 4H).
-
- A suspension of 9-oxo-5,6,7,8, 9,10-hexahydro-acridine-3-carboxylic acid (1 g, 0.42 mmols) in toluene (10 mL) was heated with phosphorous oxybromide (3.54 g, 1.2 mmols) to 100° C. for 4 h. Reaction completion was monitored by TLC. After completion, the reaction mixture was cooled to 25° C., quenched with solid ice (50 g) and the pH was adjusted to 4-5 with solid sodium bicarbonate. The precipitated solid was filtered, washed with water (250 mL) and dried under vacuum to gel the crude product as off white solid. The crude product was purified by preparative HPLC to get pure bromo compound (65 mg. 5%) as off white solid.
- 1H NMR (300 MHz, DMSO): δ=8.44 (s, 1H), 8.19-8.16 (d, 1H, J=9 Hz), 8.08-8.11 (d, 1H, J=9 Hz), 3.07 (m, 2H), 2.97 (m, 2H), 1.89 (m, 4H).
- A suspension of 9-oxo-5,6,7,8,9,10-hexahydro-acridine-3-carboxylic acid (1 g, 0.42 mmols) in toluene (10 mL) was heated with phosphorous oxybromide (3.54 g, 1.2 mmols) to 100° C. for 4 h. Reaction completion was monitored by TLC. Alter completion, the reaction mixture was cooled to 25° C., quenched with methanol (10 mL), concentrated the reaction mixture under vacuum and purified the crude product with silica gel column (60:120). Product eluted with 2% methanol in chloroform. Fractions were collected and concentrated to get the pure product as off white solid. This compound was taken as such to next step.
- 1H NMR (300 MHz, DMSO): δ=8.47-8.49 (m, 1H), 8.21-8.27 (t, 1H, J=7.5 Hz), 8.09-8.13 (m, 1H), 3.95 (s, 3H), 3.08 (m, 2H), 2.99 (m, 2H), 1.91 (m. 4H).
- To a solution of 9-Bromo-5,6,7,8-tetrahydro-acridine-3-carboxylic acid methyl ester (1 g, 0.42 mmols) in DME (15 mL) and THF (10 mL), added potassium carbonate (450 mg, 0.32 mmols), methyl boronic acid (150 mg, 0.23 mmols) and the reaction mixture was degassed with argon. Added tetrakis(triphenyl phosphine) palladium (0) (130 mg, 0.016 mmols) and the reaction mixture was heated at 90° C. for 8 h. Reaction completion was monitored by TLC. After completion, the reaction mixture was cooled to 25° C., diluted with ethyl acetate and filtered through celite. Filtrate was concentrated and purified by silica gel (60:120) column. Product eluted with 10% ethyl acetate in ether. Fractions were collected and concentrated to get the product as off while solid with 70% purity. The product was further purified by preparative HPLC.
- 1H NMR (300 MHz, CDCl3): δ=8.73 (s, 1H), 8.00-8.08 (m, 2H), 3.99 (s, 3H), 3.01-3.18 (m, 2H), 2.93 (m, 2H), 2.59 (s, 3H), 1.90-2.03 (m, 4H).
- A solution 9-methyl-5,6,7,8-tetrahydro-acridine-3-carboxylic acid methyl ester (120 mg, 0.04 mmols) in THF:water (6 mL: 4 mL) added solid sodium hydroxide (75 mg, 0.16 mmols) and heated the reaction mixture at 70° C. for 3 h. Reaction completion was monitored by TLC. Alter completion, the reaction mixture was diluted with water and washed with ethyl acetate. The aqueous layer was acidified to pH 3-4 using 1.5N hydrochloric acid solution. Precipitated product was filtered and dried to get the pure product as off white solid (25 mg, 22%). Compound was purified by preparative HPLC.
- 1H NMR (300 MHz. DMSO, TFA): δ=8.69 (s, 1H), 8.57-8.60 (d, 1H, J=9 Hz), 8.26-8.29 (d, 1H, J=9 Hz), 3.32 (m, 2H), 3.01 (m, 2H), 2.85 (s, 3H), 1.94 (m, 4H).
- To a solution of 9-Chloro-5,8,7,8-tetrahydro-acridine-3-carboxylic acid (1 g, 0.2 mmols) in ethanol (10 mL), added 50% wet palladium on carbon 10% (200 mg) and the reaction mixture was hydrogenated at 3 kg for 12 h. Reaction completion was monitored by TLC. The reaction mixture was filtered through celite, washed with ethanol and concentrated under vacuum to get the crude product. (51% by LC/MS). Purification by silica gel (60:120) chromatography with 5% methanol in chloroform and afforded 80 mg (15%) of pure product.
- 1H NMR (300 MHz. DMSO): δ=13.15 (s, 1H), 8.43 (s, 1H), 8.09 (s, 1H), 7.91-7.98 (t, 1H, J=9.6 Hz), 2.965-3.072 (m, 4H), 1.878-1.972 (m, 4H).
-
- 1 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [1-(3-methyl-benzyl)-piperidin-4-ylmethyl]-amide
- 2 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide
- 3 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-dipropylamino-ethyl)-amide
- 4 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [2-(butyl-ethyl-amino)-ethyl]-amide
- 5 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(benzyl-ethyl-amino)-propyl]-amide
- 6 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-dipropylamino-propyl)-amide
- 7 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-diethylamino-ethyl)-amide
- 8 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide
- 9 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(2,6-dimethyl-piperidin-1-yl)-propyl]-amide
- 10 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-diethylamino-propyl)-amide
- 11 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide
- 12 Azepan-1-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- 13 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(4-propyl-piperazin-1-yl)-propyl]-amide
- 14 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(benzyl-methyl-amino)-propyl]-amide
- 15 9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide
- 16 [1,4′]Bipiperidinyl-1′-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
- 17 9-chloro-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5,6,7,8-tetrahydroacridino-3-carboxamide
- 18 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 19 9-chloro-N-(3-(pyrrolidin-1-ylmethyl)phenyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 20 9-chloro-N-(3-(2-methylpiperidin-1-yl)propyl)-516,7,8-tetrahydroacridine-3-carboxamide
- 21 9-chloro-N-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 22 9-chloro-N-((1-(4-methoxybenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 23 9-chloro-N-((1-4-N,N-dimethylbenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 24 9-chloro-N-((piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 25 9-chloro-N-(3-hydroxy-3-phenyl-2-pyrrolidin-1-ylmethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 26 chlorhydrate of 9-chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-diethylamino-ethyl)-amide
- 27 N-(2-(azepan-1-yl)ethyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 28 9-chloro-N-(2-(piperidin-1-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 29 (9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(4-((1-methylpiperidin-4-yl)methyl)piperazin-1-yl)methanone
- 30 (9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(4-(1-methylpiperidin-4-yl)piperazin-1-yl)methanone
- 31 (9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(piperidin-1-yl)methanone
- 32 N-((1-benzylpiperidin-4-yl)methyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
- 33 9-chloro-N-((1-(3-phenylpropyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 34 9-chloro-N-((1-phenethylpiperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 35 9-chloro-N-(5-(diethylamino)pentan-2-yl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 36 (R)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 37 (S)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 38 9-chloro-N-(3-(dimethylamino)-2,2-dimethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- 39 9-chloro-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
- The cDNA encoding USP7 was obtained by PCR amplification from placenta mRNA. USP7 cDNA was subcloned by PCR into a baculovirus expression vector (pFastBac-HT; Invitrogen). Full-length wild-type human USP7 and its catalytic mutant (cysteine 223 replaced by alanine, C223A) were produced as N-terminally His-tagged fusions in Spodoptera frugiperda cells (Sf9, Invitrogen), using the Bac-to-Bac Baculovirus system from Invitrogen according to the manufacturer's instructions. pFastBac-HT-B-USP7 was used to transform DH10bac cells (Invitrogen), and blue/white selection was carried out on X-gal/IPTG agar plates. Bacmid DNA was prepared by an alkaline lysis procedure. The integrity of the bacmid minipreps and their orientation were checked by PCR, using generic and specific primers. Sf9 insect cells were cultured in InsectXpress medium (Cambrex) at 27° C. and transfected with the corresponding bacmid, using GeneShuttle 40 (Q-BIOgen). Viruses were recovered in the supernatant 72 h after transfection. Viruses were amplified by infecting insect cells (Sf9 or High Five cells; invitrogen) in 50 ml InsectXpress medium in a 150 cm2 cell culture flask with 500 μl of the supernatant from transfected Sf9 cells. Following the second round of amplification, infected cells were recovered by rapid SDS lysis, boiled for 5 min at 100° C., sonicated briefly and centrifuged for 20 min at 14,000 g. Expression levels in infected Sf9 cells were compared with those in uninfected cells. Fusion proteins were then allowed to bind to TALON beads (BD Biosciences, TALON metal affinity resin) for 30 min at 4° C. with gentle rocking. Beads were extensively washed (50 mM sodium phosphate buffer pH 7.0, 500 mM NaCl, 10 mM Imidazole, 0.5% Triton X-100 and 10% glycerol) and bound proteins were eluted in wash buffer supplemented with 250 mM Imidazole (Sigma). Eluted fractions were resolved on 4-12% NuPAGE gels (Novex, Invitrogen). Fractions containing high concentrations of purified proteins (purity >95%) were dialyzed (20 mM Tris HCl pH 7.6, 200 mM NaCl, 1 mM DTT, 1 mM EDTA and 10% glycerol) were aliquoted and snap frozen in liquid nitrogen before storage at −80° C.
- USP7 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01° AD Triton X-100; Bovine Serum Albumin 0.05 mg·ml−1 pH7.6). Compounds stocks (10 mM) were stored at −20° C. in DMSO. Compounds were tested at different concentrations: from 200 μM to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volumes microplates; Greiner; 10 μl final reaction volume). The substrate concentration for USP7 was 300 nM Ub-AMC (Chem. Biol., 2003, 10, p. 837-846) (Boston Biochem). The concentrations of the enzyme (USP7) in specificity assays was 100 pM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration. Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/− compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final). Readings were performed on a Pherastar □Fluorescent Reader (BMG). λ□Emission 380 nm; λ Excitation=460 nm. Data (mean values+/−standard deviation) were analyzed as % of control (no compound) and plotted as percentage versus the Log of the compound concentration using GraphPad (Prism). Data were fitted to a sigmoidal model (variable slope).
- USP5 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg·ml−1 pH 7.6). Compounds stocks (100 mM) were stored at −20° C. in DMSO. Compounds were tested at different concentrations: from 2000A to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 μl final reaction volume). The substrate concentration for USP5 was 300 nM Ub-AMC (Boston Biochem). The concentrations of the enzyme (USP5) in specificity assays was 300 pM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration. Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/− compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final). Readings were performed on a Pherastar Fluorescent Reader (BMG). λ Emission 380 nm; λ Excitation=460 nm. Data (mean values+/−standard deviation) were analyzed as % of control (no compound) and plotted as percentage versus the Log of the compound concentration using GraphPad (Prism). Data were fitted to a sigmoidal model (variable slope).
- The cDNA encoding USP8 was obtained by PCR amplification from placenta mRNA. USP8 cDNA was subcloned by PCR into a baculovirus expression vector (pFastBac-HT; Invitrogen). A cDNA encoding a mutated USP8 was generated by mutagenic PCR. The corresponding protein encodes a cysteine to alanine substitution at residue 786. The sequences were ascertained by sequencing of the entire open reading frame. Bacmids encoding USP8 were generated following DH10bac transposition. The corresponding bacmids were transfected into insect cells (Sf9). Viruses were recovered from culture supernatant and amplified twice. Insect cells (Sf9 or High Five; Invitrogen) were infected for 72 hours. Total cell lysates were harvested and lyzed in lysis buffer (
Tris HCl 50 mM pH7.6; 0.75% NP40; 500 mM NaCl; 10% glycerol; 1 mM DTT; 10 mM imidazole; Protease Inhibitor Cocktail; AEBSF 20 μg·ml−1; Aprotinin 10 μg·ml−1). Proteins were affinity purified on metal affinity resins (Talon Metal affinity resin; BD Biosciences). Bound materials were extensively washed in wash buffer (50 mM Sodium Phosphate pH 7.0; 300 mM NaCl; 10 mM imidazole; 0.5% Triton X-100; 10% glycerol) and eluted from the resin in 250 mM imidazole-containing wash buffer. Proteins were dialyzed in dialysis buffer (Tris HCl pH 7.6 20 mM; NaCl 200 mM; DTT 1 mM; EDTA 1 mM; 10% Glycerol). Proteins purifications were analyzed on 4-12% NuPAGE (Invitrogen). - USP8 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg·ml−1 pH8.8). Compounds stocks (100 mM) were stored at −20° C. in DMSO. Compounds were tested at different concentrations: from 200 μM to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 μl final reaction volume). The substrate concentration for USP8 was 300 nM Ub-AMC (Boston Biochem). The concentration of the enzyme (USP8) in specificity assays was 1.36 nM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration. Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/− compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final). Readings were performed on a Pherastar Fluorescent Reader (BMG). λ Emission 380 nm: λ Excitation=460 nm. Data (mean values+/−standard deviation) were analyzed as % of control (no compound) and plotted as percentage versus the Log of the compound concentration using GraphPad (Prism). Data were fitted to a sigmoidal model (variable slope).
- UCH-L1 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg·ml−1 pH7.6). Compounds stocks (100 mM) were stored at −20° C. in DMSO. Compounds were tested at different concentrations: from 200 μM to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 μl final reaction volume). The substrate concentration for UCH-L1 was 300 nM Ub-AMC (Boston Biochem). The concentration of the enzyme (UCH-L1) in specificity assays was 2.5 nM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration. Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/− compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final). Readings were performed on a Pherastar Fluorescent Reader (BMG). λ Emission 380 nm; λ Excitation=460 nm. Data (mean values+/−standard deviation) were analyzed as % of control (no compound) and plotted as percentage versus the Log of the compound concentration using GraphPad (Prism). Data were fitted to a sigmoidal model (variable slope).
- UCH-L3 was diluted in USP buffer (50 mM Tris HCl; 0.5 mM EDTA; 5 mM DTT; 0.01% Triton X-100; Bovine Serum Albumin 0.05 mg·ml−1 pH7.6). Compounds stocks (100 mM) were stored at −20° C. in DMSO. Compounds were tested at different concentrations: from 200 μM to 91 nM.
- Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 μl final reaction volume). The substrate concentration for UCH-L3 was 300 nM Ub-AMC (Boston Biochem). The concentration of the enzyme (UCH-L3) in specificity assays was 13 pM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration. Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/− compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final). Readings were performed on a Pherastar Fluorescent Reader (BMG). λ Emission 380 nm; λ Excitation=460 nm. Data (mean values+/−standard deviation) were analyzed as % of control (no compound) and plotted as percentage versus the Log of the compound concentration using GraphPad (Prism). Data were fitted to a sigmoidal model (variable slope).
-
Caspase 3 was diluted inCaspase 3 buffer (100 mM Hepes pH 7.5; 10% sucrose; 0.1% CHAPS). Compounds stocks (100 mM) were stored at −20° C. in DMSO. Compounds were tested at different concentrations: from 200 μM to 91 nM. - Reactions were performed as duplicates in Black 384 well plates (small volume microplates; Greiner; 10 μl final reaction volume). The substrate concentration for
caspase 3 specificity assay was 250 nM (Ac-DEVD-AMC; Promega). The concentration of the enzyme (Caspase 3) in specificity assays was 1.6 nM. The concentrations were determined in order to perform specificity assays under initial velocities at fixed substrate concentration. Compounds were pre-incubated with enzymes for 30 minutes at 25° C. Reactions were initiated by addition of substrate to the plates containing the enzymes (+/− compounds) diluted in assay buffer. Reactions were incubated for 60 minutes at 37° C. Reactions were stopped by adding acetic acid (100 mM final). Readings were performed on a Pherastar Fluorescent Reader (BMG). λ Emission 380 nm; λ Excitation=460 nm. Data (mean values+/−standard deviation) were analyzed as % of control (no compound) and plotted as percentage versus the Log of the compound concentration using GraphPad (Prism). Data were fitted to a sigmoidal model (variable slope). - HCT116 colon cancer cells were obtained from ATCC (American Type Culture Collection), and maintained in Mc Coy's 5A medium containing 10% FBS, 3 mM glutamine and 1% penicillin/streptomycin. Cells were incubated at 37° C. in a humidified atmosphere containing 5% CO2.
- Cell viability was assayed using the MTS technique in 96-well culture plates (CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay, Promega) according to the manufacturer's instructions. MTS (3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-zolium) is a MTT-derived tetrazolium that is reduced in metabolically active cells into a soluble, cell-permeant formazan. The amount of formazan, detected by its absorbance at 492 nm is proportional to the number of living, metabolically active cells.
- 103 HCT116 cells were seeded per well. 24 hours later, the medium was changed and the cells treated in triplicate with the concentrations of each compound from 100 μM to 50 nM. The compounds were diluted in 100% DMSO, whose final concentration on cells was kept at 0.5%.
- Cells were incubated with the compounds for 72 hours, and their viability then assayed by the addition of MTS for 2 hours. Absorbance at 492 nm was measured directly from the 96-well culture plates. GI50 (Growth Inhibition 50) concentrations for each compound were calculated using a sigmoidal variable slope fit (Prism 4.0, Graphpad Softwares). Values represent mean of three independent experiments.
- Methods for Evaluation of Compound Selectivity from a Panel of Deubiquitinating Enzymes Active in Cell Lysates
- The C-terminally modified vinyl sulfone derivative of ubiquitin, UbVS, was clearly helpful for a direct visualization of active DUBs in cells. This tool, which binds covalently to the cysteine active site of deubiquitinating enzymes, was successfully applied to discover and characterize novel ubiquitin/ubiquitin-like proteases and to profile active deubiquitinating enzymes in normal, virus-infected, and malignant cells (Borodovsky et al., Chem Biol 2002, 9, 1149-1159, Hemelaar et al., Mol Cell Biol 2004, 24, 84-95, Ovaa et al., Proc Natl Acad Sci USA 2004 101, 2253-2258).
- The HA-Ub-VS probe (Hemagglutin tag-Ubiquitin-Vinyl Sulfone) was used in this study to directly visualize the activity of all deubiquitinating enzymes from cell lysates. This tool was used to evaluate the activity/specificity of our small molecule compounds on USP7 relative to all deubiquitinating enzymes active in physiological conditions.
- Inducible USP7 shRNA HCT116 cells (previously treated with or without Doxycycline (2 μg/ml) for 4 days) as well as HEK293 cells were harvested and lysed on ice with a non denaturating buffer containing Tris pH7.4, 50 mM; NaCl, 150 mM; MgCl2, 5 mM; EDTA, 0.5 mM; DTT, 2 mM; ATP, 2 mM; NP40, 0.5% and glycerol, 10%. Samples were incubated at 4° C. for 1 hour and clarified. Proteins were then quantified by Bradford method (Bio-Rad Protein Assay). 25 μg of proteins from native cell lysates were treated with compounds of examples 14 and 5 (from 100 μM to 3 μM) or with NEM (N-Ethylmaleimide, a thiol-reactive compound, 5 mM) for 2 hours at room temperature. The ubiquitin labeling reaction was initiated by the addition of HA-Ub-VS (8 μg/ml) in labeling buffer (Tris pH7.6, 50 mM; MgCl2, 5 mM; EDTA, 0.5 mM; DTT, 2 mM; ATP, 2 mM; sucrose, 250 mM) and incubated at room temperature for 30 min. Samples were next heated at 100° C. for 10 minutes and briefly sonicated. They were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane and probed with antibodies against USP7 (Bethyl Lab, A300-034A), HA (BabCO, MMS-101P), and actin (Sigma, A2066). Horseradish peroxidase (HRP)-conjugated anti-mouse (Jackson Laboratories, 115-035-003) or HRP-conjugated anti-rabbit (Cell Signaling, 7074) antibodies were used as secondary antibodies. Signals were detected by enhanced chemiluminescence (ECL; Amersham) according to the reagent manufacturer's instructions.
- The results are summarized on the following table (μM):
-
Example MW USP7 USP8 USP5 Uch-L1 Uch-L3 Caspase 3 1 462.04 9.1 >200 >200 >200 >200 >200 2 371.91 11.5 >200 >200 >200 >200 >200 3 387.96 12.4 >200 >200 >200 >200 >200 4 387.96 23.5 >200 >200 >200 >200 >200 5 436.00 22.6 >200 >200 >200 >200 >200 6 401.98 23.8 >200 >200 >200 >200 >200 7 359.90 24.9 >200 >200 >200 >200 >200 8 371.91 25.6 >200 >200 >200 >200 >200 9 414.00 28.7 >200 >200 >200 >200 >200 14 421.97 28.1 >200 >200 >200 >200 >200 10 373.93 29.2 >200 >200 >200 >200 >200 11 331.85 29.8 >200 >200 >200 >200 >200 12 342.87 37.9 >200 >200 >200 >200 >200 13 429.01 37.9 >200 >200 >200 >200 >200 15 400.96 43.0 >200 >200 >200 >200 >200 16 411.98 46.0 >200 >200 >200 >200 >200 17 371.91 13.7 >200 >200 >200 >200 >200 18 433.98 18.3 >200 >200 >200 >200 >200 19 419.96 8.2 >200 >200 >200 >200 >200 20 399.97 45.5 >200 >200 >200 >200 >200 21 433.98 16.3 >200 >200 >200 >200 >200 22 478.04 27.4 >200 >200 >200 >200 >200 23 491.08 33.1 >200 >200 >200 >200 >200 24 357.88 45.2 −200 >200 >200 >200 >200 25 478.04 59.5 >200 >200 >200 >200 >200 26 432.82 30.5 >200 >200 >200 >200 >200 - The results are summarized on the following table (μM):
-
Cell viability (MTS): Example MW MLogP HCT116 GI50 Day 3 (μM) 1 462.04 4.5 2.0 2 371.91 3.3 5.0 3 387.96 3.5 3.5 4 387.96 3.5 4.0 5 436.00 4.1 4.0 6 401.98 3.7 3.9 7 359.9 3.0 4.3 8 371.91 3.3 5.9 9 414.00 3.9 3.6 10 373.93 3.3 5.0 11 331.85 2.6 7.8 12 342.87 3.9 20 13 429.01 3.1 5.9 14 421.97 3.9 4.1 15 400.96 2.7 7.4 16 411.98 3.9 13.5 17 371.91 3.3 6.9 18 433.98 4.1 4.3 19 419.96 4.1 4.1 20 399.97 3.7 8.4 21 433.98 4.1 3.5 22 478.04 4 3.3 23 491.08 4.1 1.8 24 357.88 3 8.3 25 478.04 3.7 5.6 26 432.82 3.5 5.6 27 385.94 3.5 10.0 28 371.91 3.3 8.8 29 441.02 3.3 7.3 30 426.99 3.1 12.5 31 328.84 3.6 11.4 32 448.01 4.3 3.1 33 476.06 4.7 2.0 34 462.04 4.5 2.8 35 401.98 3.7 8.2 36 371.91 3.3 9.1 37 371.91 3.3 8.7 38 373.93 3.3 11 39 433.98 4.1 7.6 - As summarized in
FIG. 1A , the C-terminally modified vinyl sulfone derivative of ubiquitin (HA-Ub-VS), binds covalently to the cysteine active site of deubiquitinating enzymes. This labeling followed by immunoblot with the anti-HA antibody allowed the identification of all active deubiquitinating enzymes from HCT116 cell lysates (FIG. 1B ). In addition, active USP7 was identified in this assay as indicated by the mobility shift observed following immunoblot with anti-USP7 antibody. This labeling, specific to the active form of DUBs, is inhibited by a thiol-reactive compound (NEM) in a non-specific manner (FIG. 1B ). - To localize the signal corresponding to active USP7 in the panel of active DUBs following HA-Ub-VS labeling, the inducible shRNA USP7 HCT116 cell line was treated with Doxycycline (Dox) thus enabling the expression of USP7 shRNA. Interestingly, only one band was decreased following USP7 silencing thus clearly indicating that this band corresponds to HA-Ub-VS-USP7 (
FIG. 2A ). A quantification showing this specific decrease is presented inFIG. 2B (quantification performed using the image analysis software, GeneTools, Syngene). USP7 silencing induced by Doxycycline treatment was confirmed with anti-USP7 antibody. - A study with small molecule compound was first performed with a fixed dose of the compound of example 14 (50 μM) on HCT116 cell lysates. Interestingly, only one band was decreased following treatment at the size corresponding to HA-Ub-VS-USP7 (
FIG. 3A ). A quantification showing this specific decrease is presented inFIG. 3B (quantification performed using the image analysis software, GeneTools, Syngene). This effect on USP7 activity was confirmed with anti-USP7 antibody as indicated by the mobility shift observed between the treated and non-treated samples. - HCT116 cells were next treated either with different doses of compounds of examples 14 and 5 or with Doxycycline to induce USP7 silencing. Localization of the HA-Ub-VS-USP7 protein was facilitated by the specific silencing of USP7 as indicated in the presence of doxycycline (
FIG. 4A , +Dox). Once this band identified, cell lysates were treated with different doses of compounds of examples 14 and 5 and a specific and dose-dependent decrease of the HA-Ub-VS-USP7 protein level was clearly observed (FIGS. 4A and B). This effect on USP7 activity was confirmed with anti-USP7 antibody as indicated by the mobility shift observed between the treated and non-treated samples. Interestingly, these findings were also confirmed in cell lysates prepared from HEK293 cells (FIGS. 5A and B). These results thus demonstrate that different compounds from this new chemical series (compounds of examples 14 and 5) inhibit specifically and dose-dependently USP7 deubiquitinating activity over a panel of active DUBs in physiological conditions. - For compounds 26 to 38, the in-vitro assays on USP7 and USP8 were carried out according to the following procedure
- A cDNA encoding the fusion protein between ubiquitin and the ribosomal protein L40 (ub52 or uba52 or ubiquitin-L40) was amplified from human RNA using a proprietary human placenta library. The cDNA was subcloned into a bacterial expression vector (pGEX-2T, GE Healthcare), including an additional flag tag at the carboxyl end of the encoded protein. The following primers were used for subcloning in frame with the GST tag the ubiquitin-L40 into pGEX-2T: 5′-cgtggatccatgcagatctttgtgaagaccctc-3′ (SEQ ID NO:10) and 5′-gcgaattctttatcgtcatcgtctttgtagtctttgaccttcttcttgggacg-3′ (SEQ ID NO:11) into BamHI & EcoRI restriction sites.
- For production and purification of recombinant proteins, the plasmid pGEX-2T-Ub52-flag was transformed into E. coli BL21 (Stratagene), grown in LB medium supplemented with 100 mg/ml ampicilin (LB ampi) at 37° C. overnight and then diluted 1/100 in LB ampi. The cells were incubated at 37° C. until an A600=0.6-0.8 was reached. After induction with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG), the culture was incubated at 30° C. for 180 min.
- Cells were harvested by centrifugation for 15 min at 7000×g at 4° C. Bacterial pellets were lysed in NETN (Tris HCl pH 8.0; EDTA 1 mM; NP40 0.5%; protease inhibitor cocktail, PMSF 1 mM) and briefly sonicated. Insoluble material was removed by centrifugation 30 min at 14000×g. GST-Ub52-flag proteins were purified according to Everett R D et al., EMBO J. (1997) 16, 1519-1530. Briefly, soluble fraction was incubated on Glutathione beads pre-equilibrated in NETN buffer+0.5% Milk for 120 min at 4° C. Flow Through was recovered. Beads were extensively washed: the last wash was performed in Tris HCl pH 7.6 20 mM;
NaCl 100 mM; MgCl2 12 mM. Elutions were performed using 20 mM Reduced Glutathione in 50 mM Tris HCl pH 8.0, NaCl 120 mM. All fractions were resolved on a 4-12% NuPAGE following 0.1 M DTT treatment and denaturation and stained with Coomassie Brilliant Blue. Elutions were dialysed over night at 4° C. in Tris HCl pH 7.6 20 mM;NaCl 50 mM; DTT 0.5 mM. - The present examples 26 to 38 makes it possible to validate the use of GST-Ub52-Flag in an assay based on the time-resolved measurement of fluorescence emitted by radioactive transfer in homogenous medium.
- The reagents used were as follows:
-
- Anti-flag antibody-europium cryptate conjugate referred to as anti-Flag-K (CIS bio international), solution at 0.2 μM in 0.8 M KF, 0.1% Bovine Serum Albumin,
Tris HCl 25 mM pH 7.6. - Anti-GST antibody-XL665 conjugate (CIS bio international), solution at 2.6 μM in 0.8 M KF, 0.1% Bovine Serum Albumin,
Tris HCl 25 mM pH 7.6. - GST-Ub52-Flag solution at 14.75 μM & MBP_Ub52 at 37.7 μM prepared from the stock solution described above in 50 mM Tris HCl pH 7.6, EDTA 0.5 mM, Bovine Serum Albumin 0.05%,
DTT 5 mM.
- Anti-flag antibody-europium cryptate conjugate referred to as anti-Flag-K (CIS bio international), solution at 0.2 μM in 0.8 M KF, 0.1% Bovine Serum Albumin,
- The assay is carried out on multiwell assay plates. The plates are analyzed on a PHERAstar fluorimeter (BMG) after an overnight incubation at 4° C. (excitation 337 nm, emission 620 and 665 nm).
- Assaying the Activity of Enzymes of the Deubiquitinating Type with Ubiquitin-Ribosomal Protein Fusion
- The reagents used were as follows:
-
- Solution of USP7 at 200 pM and USP8 at 400 pM in 50 mM Tris HCl pH 7.6, Bovine Serum Albumin 0.05%,
DTT 5 mM. - Anti-Flag-K (CIS bio international), solution at 0.2 μM in 0.8 M KF, 0.1% Bovine Serum Albumin,
Tris HCl 25 mM pH 7.6. - Anti-GST antibody-XL665 conjugate (CIS bio international), solution at 2.6 μM in 0.8 M KF, 0.1% Bovine Serum Albumin,
Tris HCl 25 mM pH 7.6. - GST-Ub52-flag solution at 14.75 μM & MBP_Ub52 at 37.7 μM are prepared by dilutions from the stock solution described above in 50 mM Tris HCl pH 7.6, EDTA 0.5 mM, Bovine Serum Albumin 0.05%,
DTT 5 mM.
- Solution of USP7 at 200 pM and USP8 at 400 pM in 50 mM Tris HCl pH 7.6, Bovine Serum Albumin 0.05%,
- The enzyme reaction is carried out by mixing GST-Ub52-flag solution with 5 μl of USP7 solution (200 pM final) or 5 μl of USP8 (400 pM final). This mixture is incubated for one hour at room temperature on a multiwell assay plate. A 10 μl mixture of 5 μl of anti-Flag-K solution (0.2 μM) plus 5 μl of anti-GST-XL665 antibody (2.6 μM) is added to each well of the multiwell assay plate. The plate is read after an overnight incubation at 4° C. on a PHERAstar fluorimeter (BMG).
- The decrease in the signal correlates with the increase in enzyme activity i.e. the cleavage of GST-Ub52-Flag substrate. The format used is therefore entirely suitable for a method of assaying an enzyme of the deubiquitinating type such as ubiquitin specific protease, but also for determining a modulator of this enzyme activity.
- The same procedures as mentioned above for assaying the activity of enzymes of the deubiquitinating type are carried out but the various reaction mixtures are incubated with identical enzyme concentration, in the presence or absence of a test compounds 26 to 38. Data (mean values+/−standard deviation) were analyzed as % of control (no compound) and plotted as percentage versus the Log of the compound concentration using GraphPad (Prism). Data were fitted to a sigmoidal model (variable slope) and IC50 (μM) was determined and presented in the following table.
-
Example MW USP7 USP8 27 385.94 15.4 >200 28 371.91 11.9 >200 29 441.02 8.5 >200 30 426.99 23 >200 31 328.84 24.5 >200 32 448.01 17.6 >200 33 476.06 16.4 >200 34 462.04 24.5 >200 35 401.98 36.9 >200 36 371.91 44.4 >200 37 371.91 25.9 >200 38 373.93 49.2 >200 39 433.98 38.5 >200
Claims (17)
1. A compound of formula (I):
wherein:
i is an integer chosen from 0, 1, 2 or 3 when n is 1, or from 0, 1, 2, 3 or 4 when n is 2, or from 0, 1, 2, 3, 4 or 5 when n is 3;
j is an integer chosen from 0, 1, 2 or 3;
k is an integer chosen from 0 or 1;
n and n′ identical or different are integers chosen from 0, 1, 2 or 4, provided that 2≦n+n′≦4;
Z is CH2<, —HC<, —N<, NH< or O<;
each Ri located on any available position of the A ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, CF3, COR, COOR, CONRR′;
each Rj located on any available position of the C ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, COR, COOR, CONRR′;
Rk is independently chosen from halogen, alkyl, alkoxy, cyano;
X is chosen from H, alkyl, aryl, -alkylaryl, wherein said alkyl and/or aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
Y is chosen from:
(CT2′)pNRaRb where
Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl or arylalkyl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, ═O, OR, NRR′, COR, COOR, CONRR′;
or Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; CN; CF3; OR; NRR′; COR; COOR; CONRR′; said heterocycle being optionally fused with an aryl;
p is an integer chosen from 0 to 6;
each T′, identical or different is independently chosen from H or a linear or branched alkyl wherein the alkyl is optionally substituted by one or more OR, aryl;
is a saturated or partially unsaturated heterocycle or heteroaryl, mono or bicyclic, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; -alkylaryl; OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl or -alkylaryl wherein said aryl is optionally substituted by a linear or branched alkyl, halogen, OR, COR or NR′R;
q is an integer chosen from 0 to 6;
each T, identical or different is independently chosen from H or alkyl;
(CHT)r-aryl wherein:
said mono or bicyclic aryl is optionally substituted by one or more of alkyl; OR; CF3, SO2NRR′; —C(═O)—R; Halogen; CN; —NRR′; CONRR; C(═O)—Oalkyl wherein said alkyl is optionally substituted by NRR′ or NR″R′″; and/or said mono or bicyclic aryl is optionally fused with a monocyclic 5 to 7 membered heterocycle;
r is an integer chosen from 0 to 6;
each T, identical or different is independently chosen from H or alkyl;
where R″ and R′″ together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; CN; CF3; OR; NRR′; COR; COOR; CONRR′;
(CHT)s-(C3-C7)cycloalkyl where
s is an integer chosen from 0 to 6;
each T, identical or different is independently chosen from H or alkyl;
said cycloalkyl is monocyclic, or fused with an aryl;
alkyl optionally substituted by CN, Oalkyl;
U—S(O)t-alkyl where
t is an integer chosen from 0, 1 or 2;
—U— is an alkylene optionally substituted by one or more of OR; ═O; CF3, SO2NRR′; —C(═O)—R; Halogen; CN; —NRR′; CONRR; C(═O)OR;
or X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
being optionally substituted by one or more of: ═O; Hal, CN, NRR′, C(═O)alkyl, alkyl; cycloalkyl; heterocycle; C(═O)—Oalkyl; -alkylheterocycle; aryl or -alkylaryl where said aryl is optionally fused with an heterocycle and/or said aryl being optionally substituted by alkyl or COalkyl; said heterocycle being optionally substituted by an alkyl;
being optionally fused with an aryl;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl, or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein k=1 and Rk is a halogen.
3. The compound according to claim 1 , wherein n′ is 1 and n is 2.
4. The compound according to claim 1 , wherein:
X is defined as in claim 1 and Y is chosen from:
(CT2′)pNRaRb where
Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl, -alkylaryl, wherein said aryl is optionally substituted by alkyl;
p is 0 to 4;
or where
Ra and Rb together form with the N atom to which they are attached a 5 to 7-membered heterocycle optionally comprising one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl where aryl is optionally substituted by halogen; ═O; CN; CF3; OR; NRR′; COR; COOR; CONRR′; said heterocycle being optionally fused with an aryl and;
p is chosen from 2 or 3;
each T′, identical or different, is independently chosen from H or a linear or branched alkyl, wherein the alkyl is optionally substituted by one or more OR, aryl;
is a bicyclic saturated or partially unsaturated heterocycle or heteroaryl, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; OR; C(═O)OR; aryl or -alkylaryl wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R;
q is an integer chosen from 0, 1, 2 or 3;
each T, identical or different is independently chosen from H or alkyl;
(CHT)r-aryl wherein:
said aryl is mono or bicyclic, optionally substituted by one or more of alkyl, OR, SO2NRR′; —C(═O)—R; Halogen; CN; C(═O)—Oalkyl, wherein said alkyl is optionally substituted by NRR′ or NR″R′″; and said aryl is optionally fused with an heterocycle;
r is an integer chosen from 0, 1, 2 or 3;
each T, identical or different is independently chosen from H or alkyl;
or
X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
being optionally substituted by one or more of: ═O; alkyl; cycloalkyl; heterocycle; -alkylheterocyle; C(═O)—Oalkyl; aryl or -alkylaryl where said aryl is optionally substituted by alkyl; said heterocycle being optionally substituted by an alkyl;
being optionally fused with an aryl;
where, preferably, q is 1, 2 or 3, r is 1, 2 or 3.
5. The compound according to claim 1 , wherein:
n′=1, n=2 or 3;
X is defined as in claim 1 and Y is chosen from:
(CT2′)pNRaRb where
Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl, -alkylaryl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
or Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle optionally comprising one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; ═O; CN; CF3; OR; NRR′; COR; COOR; CONRR′; said heterocycle being optionally fused with an aryl;
p is an integer chosen from 2 to 3;
each T′, identical or different is independently chosen from H or a linear or branched alkyl; wherein the alkyl is optionally substituted by one or more OR, aryl; in one embodiment at least one of T′ is different from H; or
is saturated or partially unsaturated heterocycle or heteroaryl, mono or bicyclic, comprising 1, 2 or 3 heteroatom(s) chosen from N, O or S, optionally substituted by one or more of alkyl; -alkylaryl; OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R;
q is 1, 2 or 3;
each T, identical or different is independently chosen from H or alkyl;
(CHT)r-aryl wherein:
said aryl is a monocyclic aryl and is optionally substituted by one or more of alkyl, SO2NRR′; —C(═O)—R; CN; C(═O)—Oalkyl; wherein said alkyl is substituted by NRR′ or NR″R′″;
r is an integer chosen from 0 to 6;
each T, identical or different is independently chosen from H or alkyl;
where R″ and R′″ together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; CN; CF3; OR; NRR′; COR; COOR; CONRR′;
or X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
being optionally substituted by one or more of: ═O; alkyl; cycloalkyl; heterocycle; -alkylheterocycle; C(═O)—Oalkyl; -alkylaryl where said aryl is optionally fused with an heterocycle and/or said aryl being optionally substituted by alkyl or COalkyl; said heterocycle comprising one or two nitrogen atom and being optionally substituted by an alkyl;
being optionally fused with an aryl;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl.
6. The compound according to claim 1 , wherein
n′=1, n=2 or 3;
X is chosen from H, alkyl, aryl, -alkylaryl, wherein said alkyl and/or aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
and Y is chosen from:
(CT2′)pNRaRb where
Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl, -alkylaryl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, OR, NRR′, COR, COOR, CONRR′;
p is 1, 2 or 3; or
Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle wherein the carbon atom adjacent to the heteroatom is optionally substituted by an alkyl; said heterocycle being optionally fused with an aryl;
p is 3 or 4; or
Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; CN; CF3; OR; NRR′; COR; COOR; CONRR′;
p is an integer chosen from 0 to 6;
each T′, identical or different, is independently chosen from H or a linear or branched alkyl, wherein the alkyl is optionally substituted by one or more OR, aryl, and at least one of T′ is different from H.
(CHT)r-aryl wherein:
said aryl is a monocyclic aryl and is optionally substituted by one or more of alkyl, SO2NRR′; —C(═O)—R; CN; C(═O)—Oalkyl; wherein said alkyl is substituted by NRR′ or NR″R′″;
r is an integer chosen from 0 to 6;
each T, identical or different is independently chosen from H or alkyl;
is a saturated monocyclic five membered heterocycle comprising a nitrogen atom and substituted by an alkyl, provided that the alkyl is not an ethyl, -alkylaryl, OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R; or a monocyclic 6 membered heterocycle comprising an nitrogen atom and optionally substituted by one or more of -alkylaryl, OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by halogen, COR, OR or NR′R;
q is an integer chosen from 0 to 6;
each T, identical or different is independently chosen from H or alkyl;
or X and Y together form with the N atom to which they are attached an heterocycle comprising said N atom and optionally one or two more heteroatoms, said heterocyle being optionally insaturated and/or
being optionally substituted by one or more of: ═O; alkyl; cycloalkyl; heterocycle; -alkylheterocycle; C(═O)—Oalkyl; -alkylaryl where said aryl is optionally fused with an heterocycle and/or said aryl being optionally substituted by alkyl or COalkyl; said heterocycle comprising one or two nitrogen atom and being optionally substituted by an alkyl;
being optionally fused with an aryl;
7. The compound according to claim 1 , wherein the compound is of the following formula:
wherein:
i is an integer chosen from 0, 1, 2, 3 or 4;
j is an integer chosen from 0, 1, 2 or 3;
each Ri located on any available position of the A ring is identical or different and chosen from halogen, alkyl, aryl, -alkylaryl, OR, NRR′, CN, CF3, COR, COOR, CONRR′;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl;
X is H
Y is chosen from:
(CHT)r-aryl wherein:
said aryl is a monocyclic aryl and is optionally substituted by one or more of alkyl, SO2NRR′; —C(═O)—R; CN; —NRR′, CONRR, C(═O)—Oalkyl; wherein said alkyl is substituted by NRR′ or NR″R′″;
r is an integer chosen from 0 to 6;
each T is H;
where R″ and R′″ together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; alkyl; CN; CF3; OR; NRR′; COR; COOR; CONRR′;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl;
(CT2′)pNRaRb where
when each T′ is H,
Ra and Rb together form with the N atom to which they are attached
a N comprising 6-membered mono substituted heterocycle wherein the carbon atom adjacent to the heteroatom is substituted by an alkyl; and p is 1, 3 or 4; or
a N-comprising 6-membered heterocycle and p is 1 to 4; or
a N-comprising 5-membered heterocycle wherein the carbon atom adjacent to the heteroatom is substituted by an alkyl; and p is 1 to 4; or
a N-comprising 7-membered heterocycle optionally substituted by an alkyl and p is 1, 2 or 4; or
a N-comprising 5-membered heterocycle and p is 1, 2 or 4;
a N-comprising 5- to 7-membered heterocycle substituted by one or more of halogen, -alkylaryl, or aryl, wherein said aryl is optionally substituted by one or more of halogen, —CN, CF3; OR; NRR′; COR; COOR; CONRR′;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl;
when each T′, identical or different, is independently chosen from H or a linear or branched alkyl, wherein the alkyl is optionally substituted by one or more OR, aryl, and at least one of the T′ is different from H,
Ra and Rb, identical or different, are independently chosen from H, alkyl, aryl or arylalkyl, wherein said aryl is optionally substituted by halogen, alkyl, CN, CF3, ═O, OR, NRR′, COR, COOR, CONRR′; and p is an integer chosen from 0 to 6; or
Ra and Rb together form with the N atom to which they are attached a N comprising 5 to 7-membered heterocycle which may comprise one or two more heteroatoms chosen from N, O or S, said heterocycle being optionally substituted by one or more of halogen; ═O; alkyl; -alkylaryl or aryl wherein said aryl is optionally substituted by halogen; CN; CF3; OR; NRR′; COR; COOR; CONRR′; and p is an integer chosen from 0 to 6;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl,
wherein:
is
a saturated monocyclic 5-membered heterocycle comprising a nitrogen atom and substituted by an alkyl, provided that the alkyl is not an ethyl; -alkylaryl; OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by alkyl, halogen, OR, COR or NR′R; or
a monocyclic 6 membered heterocycle comprising an nitrogen atom and optionally substituted by one or more of -alkylaryl, OR; C(═O)OR; ═O; CN; CF3; COR; NRR′; CONRR′; aryl; wherein said aryl is optionally substituted by halogen, COR, OR or NR′R; q is an integer chosen from 0 to 6;
each T, identical or different is independently chosen from H or alkyl;
where R and R′, identical or different are independently chosen from H, alkyl, aryl, -alkylaryl;
or X and Y together form with the N atom to which they are attached an heterocycle; comprising said N atom and optionally one or two more heteroatoms; said heterocyle is optionally insaturated and/or is optionally substituted by one or more heterocycle or -alkylheterocycle said heterocycle, comprising one or two heteroatom, and being optionally substituted by an alkyl;
or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1 , wherein:
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [1-(3-methyl-benzyl)-piperidin-4-ylmethyl]-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-dipropylamino-ethyl)-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [2-(butyl-ethyl-amino)-ethyl]-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(benzyl-ethyl-amino)-propyl]-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-dipropylamino-propyl)-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-diethylamino-ethyl)-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(2,6-dimethyl-piperidin-1-yl)-propyl]-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-diethylamino-propyl)-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide
Azepan-1-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(4-propyl-piperazin-1-yl)-propyl]-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(benzyl-methyl-amino)-propyl]-amide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide
[1,4′]Bipiperidinyl-1′-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
9-chloro-N-(3-(2-methylpiperidin-1-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-(pyrrolidin-1-ylmethyl)phenyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-(4-methoxybenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-4-N,N-dimethylbenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-hydroxy-3-phenyl-2-pyrrolidin-1-ylmethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
N-(2-(azepan-1-yl)ethyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(2-(piperidin-1-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
(9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(44(1-methylpiperidin-4-yl)methyl)piperazin-1-yl)methanone
(9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(4-(1-methylpiperidin-4-yl)piperazin-1-yl)methanone
(9-chloro-5,6,7,8-tetrahydroacridine-3-yl)(piperidin-1-yl)methanone
N-((1-benzylpiperidin-4-yl)methyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-(3-phenylpropyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-phenethylpiperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(5-(diethylamino)pentan-2-yl)-5,6,7,8-tetrahydroacridine-3-carboxamide
(R)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
(S)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-(dimethylamino)-2,2-dimethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
Chlorhydrate of 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid (2-diethylamino-ethyl)amide or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1 , chosen among:
9-chloro-N-(3-(2-methylpiperidin-1-yl)propyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-(pyrrolidin-1-ylmethyl)phenyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-(4-methoxybenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-4-N,N-dimethylbenzyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-hydroxy-3-phenyl-2-pyrrolidin-1-ylmethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-Chloro-5,6,7,8-tetrahydro-acridine-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide
Azepan-1-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
[1,4′]Bipiperidinyl-1′-yl-(9-chloro-5,6,7,8-tetrahydro-acridin-3-yl)-methanone
N-(2-(azepan-1-yl)ethyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(2-(piperidin-1-yl)ethyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
(9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(44(1-methylpiperidin-4-yl)methyl)piperazin-1-yl)methanone
(9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(4-(1-methylpiperidin-4-yl)piperazin-1-yl)methanone
(9-chloro-5,6,7,8-tetrahydroacridin-3-yl)(piperidin-1-yl)methanone
N-((1-benzylpiperidin-4-yl)methyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-(3-phenylpropyl)piperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-((1-phenethylpiperidin-4-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(5-(diethylamino)pentan-2-yl)-5,6,7,8-tetrahydroacridine-3-carboxamide
(R)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
(S)-9-chloro-N-((1-ethylpyrrolidin-2-yl)methyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
9-chloro-N-(3-(dimethylamino)-2,2-dimethylpropyl)-5,6,7,8-tetrahydroacridine-3-carboxamide
Chlorhydrate of 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid (2-diethylamino-ethyl)amide or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof.
10. Process for preparing a compound according to claim 1 , comprising the reaction of a corresponding compound of formula (VII):
12. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof, with a pharmaceutical acceptable excipient.
13. A compound of formula (I) as defined in claim 1 or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof for use for inhibiting a USP.
14. The compound for use according to claim 13 for inhibiting USP7.
15. A compound according to claim 1 or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and metastasis, neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, immunological disorders, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, viral infections and diseases, and/or viral infectivity and/or latency, bacterial infections and diseases.
16. The compound for use according to claim 15 , wherein said viral infections and diseases are chosen from herpes simplex-1 or -2 viral infections, hepatitis A, hepatitis C, SARS coronavirus infection and disease, Epstein-Barr virus, rhinoviral infections and diseases, adenoviral infections and diseases, poliomyelitis.
17. A combination comprising a compound of formula (I) as defined in claim 1 or a tautomer thereof, and/or a pharmaceutically acceptable salt thereof, with one or more active agents chosen from anti-cancer agents, neurological agents, thrombolytic agents, antioxidant agents. anti-infective, anti-hypertensive agents, diuretic agents, thrombolytic agents, immunosuppressive agents, cardiovascular agents, immunomodulatory agents, anti-inflammatory agents, antiviral agents, anti-bacterial agents.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/521,978 US20130023521A1 (en) | 2010-01-15 | 2011-01-17 | Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
US14/488,601 US9328093B2 (en) | 2010-01-15 | 2014-09-17 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29539910P | 2010-01-15 | 2010-01-15 | |
US12/855,983 US20110177105A1 (en) | 2010-01-15 | 2010-08-13 | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
EP10172844A EP2357176A1 (en) | 2010-01-15 | 2010-08-13 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
EP10172844.2 | 2010-08-13 | ||
US13/521,978 US20130023521A1 (en) | 2010-01-15 | 2011-01-17 | Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
PCT/EP2011/050523 WO2011086178A1 (en) | 2010-01-15 | 2011-01-17 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/885,983 Continuation US20110009809A1 (en) | 2008-03-20 | 2010-09-20 | Epilation device |
PCT/EP2011/050523 A-371-Of-International WO2011086178A1 (en) | 2010-01-15 | 2011-01-17 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/488,601 Division US9328093B2 (en) | 2010-01-15 | 2014-09-17 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130023521A1 true US20130023521A1 (en) | 2013-01-24 |
Family
ID=42829956
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/855,983 Abandoned US20110177105A1 (en) | 2010-01-15 | 2010-08-13 | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
US13/521,978 Abandoned US20130023521A1 (en) | 2010-01-15 | 2011-01-17 | Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
US14/488,601 Expired - Fee Related US9328093B2 (en) | 2010-01-15 | 2014-09-17 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/855,983 Abandoned US20110177105A1 (en) | 2010-01-15 | 2010-08-13 | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/488,601 Expired - Fee Related US9328093B2 (en) | 2010-01-15 | 2014-09-17 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
Country Status (12)
Country | Link |
---|---|
US (3) | US20110177105A1 (en) |
EP (2) | EP2357176A1 (en) |
JP (1) | JP6005524B2 (en) |
KR (1) | KR101800164B1 (en) |
CN (1) | CN102781919B (en) |
CA (1) | CA2786957C (en) |
DK (1) | DK2523938T3 (en) |
ES (1) | ES2523383T3 (en) |
PL (1) | PL2523938T3 (en) |
PT (1) | PT2523938E (en) |
SI (1) | SI2523938T1 (en) |
WO (1) | WO2011086178A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
EA027908B1 (en) | 2012-12-21 | 2017-09-29 | Эпизим, Инк. | Prmt5 inhibitors and uses thereof |
EP2801569A1 (en) | 2013-05-09 | 2014-11-12 | Ikerchem, S.L. | Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings |
CN105251020B (en) * | 2015-09-29 | 2018-10-09 | 武汉大学 | Ubiquitin-specific protease 4(USP4)Function in treating myocardial hypertrophy and application |
CA3001452A1 (en) | 2015-10-09 | 2017-04-13 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
EP3481803B1 (en) | 2016-07-08 | 2020-09-02 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
CN111108105B (en) | 2017-09-22 | 2023-03-31 | 朱比兰特埃皮帕德有限公司 | Heterocyclic compounds as PAD inhibitors |
BR112020007607A2 (en) | 2017-10-18 | 2020-09-29 | Jubilant Epipad LLC | compounds of formulas (i), (ii) and (iii); processes for preparing compounds of formulas (i), (ii) and (iii); pharmaceutical composition; compounds; method for inhibiting one or more pad families in a cell; method of treating a condition mediated by one or more pads; compound of formula (i), formula (ii) and formula (iii); use of the compound; method for treating and / or preventing a condition; method for the treatment of rheumatoid arthritis; and cancer treatment method |
JP7279057B6 (en) | 2017-11-06 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
SG11202004537UA (en) | 2017-11-24 | 2020-06-29 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
AU2019234185A1 (en) | 2018-03-13 | 2020-10-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
CN115557890A (en) * | 2022-09-01 | 2023-01-03 | 宁波大学 | Polysubstituted acridone alkyl derivative and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1886481A (en) * | 1927-11-07 | 1932-11-08 | Soc Of Chemical Ind | Unilaterally acylated diamines and process of making same |
WO2006072048A2 (en) | 2004-12-30 | 2006-07-06 | The Trustees Of Princeton University | Compositions and methods for identifying modulators of hausp |
DE602005010421D1 (en) | 2005-08-05 | 2008-11-27 | Hybrigenics Sa | New Cysteine Protease Inhibitors and Their Therapeutic Applications |
-
2010
- 2010-08-13 EP EP10172844A patent/EP2357176A1/en not_active Withdrawn
- 2010-08-13 US US12/855,983 patent/US20110177105A1/en not_active Abandoned
-
2011
- 2011-01-17 US US13/521,978 patent/US20130023521A1/en not_active Abandoned
- 2011-01-17 KR KR1020127021238A patent/KR101800164B1/en active IP Right Grant
- 2011-01-17 CA CA2786957A patent/CA2786957C/en not_active Expired - Fee Related
- 2011-01-17 WO PCT/EP2011/050523 patent/WO2011086178A1/en active Application Filing
- 2011-01-17 SI SI201130305T patent/SI2523938T1/en unknown
- 2011-01-17 PL PL11701220T patent/PL2523938T3/en unknown
- 2011-01-17 DK DK11701220.3T patent/DK2523938T3/en active
- 2011-01-17 PT PT117012203T patent/PT2523938E/en unknown
- 2011-01-17 JP JP2012548453A patent/JP6005524B2/en not_active Expired - Fee Related
- 2011-01-17 ES ES11701220.3T patent/ES2523383T3/en active Active
- 2011-01-17 EP EP11701220.3A patent/EP2523938B1/en not_active Not-in-force
- 2011-01-17 CN CN201180010555.9A patent/CN102781919B/en not_active Expired - Fee Related
-
2014
- 2014-09-17 US US14/488,601 patent/US9328093B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
Non-Patent Citations (3)
Title |
---|
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface pg. 1-15. * |
IDS NPL document filed 11/11/2013: * |
Venkatesh et al., J. Pharm. Sci. 89, 145-54 (2000). * |
Also Published As
Publication number | Publication date |
---|---|
WO2011086178A1 (en) | 2011-07-21 |
US20150072973A1 (en) | 2015-03-12 |
KR101800164B1 (en) | 2017-11-22 |
US9328093B2 (en) | 2016-05-03 |
US20110177105A1 (en) | 2011-07-21 |
ES2523383T3 (en) | 2014-11-25 |
EP2523938A1 (en) | 2012-11-21 |
CA2786957A1 (en) | 2011-07-21 |
CN102781919B (en) | 2016-01-20 |
JP6005524B2 (en) | 2016-10-12 |
EP2523938B1 (en) | 2014-09-03 |
JP2013517257A (en) | 2013-05-16 |
DK2523938T3 (en) | 2014-10-27 |
SI2523938T1 (en) | 2014-12-31 |
PL2523938T3 (en) | 2015-02-27 |
CN102781919A (en) | 2012-11-14 |
EP2357176A1 (en) | 2011-08-17 |
KR20120125629A (en) | 2012-11-16 |
CA2786957C (en) | 2018-02-27 |
PT2523938E (en) | 2014-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9328093B2 (en) | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | |
US9546150B2 (en) | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | |
USRE36256E (en) | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | |
US10975063B2 (en) | Compound, and production method thereof, and methods of treatment using the compound | |
US5714493A (en) | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | |
USRE37650E1 (en) | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | |
WO1995015758A1 (en) | Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase | |
Sundriyal et al. | Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity | |
EP2208725A1 (en) | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | |
Hu et al. | Identification of selective homeodomain interacting protein kinase 2 inhibitors, a potential treatment for renal fibrosis | |
NZ621827B2 (en) | Selective and reversible inhibitors of ubiquitin specific protease 7 | |
TW202235077A (en) | Usp7 binding survival-targeting chimeric (surtac) molecules & uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HYBRIGENICS SA, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOPEZ, ROMAN;COLLAND, FREDERIC;SIGNING DATES FROM 20120810 TO 20120828;REEL/FRAME:029099/0314 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |